<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0107245461
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tepkinly
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Epcoritamab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        concentrate for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2789.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ABBVIE Deutschland GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01-ANTINEOPLASTIC AGENTS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tepkinly &nbsp;is a cancer medicine that contains the active substance epcoritamab. Tepkinly &nbsp;is used on its own (monotherapy) to treat adult patients who have a blood cancer called diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL)when the disease has come back or did not respond to previous treatment after at least two prior therapies.</p><p>&nbsp;</p><p><strong>How Tepkinly works </strong></p><p>&nbsp;</p><p>Epcoritamab is specifically designed to help your own immune system to attack cancer (lymphoma) cells. Epcoritamab acts by attaching to your body&rsquo;s immune cells and cancer cells, bringing them together, so that your immune system can destroy the cancer cells.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Tepkinly </strong></p><p>&nbsp;</p><p>If you are allergic to epcoritamab or any of the other ingredients of this medicine (listed in section 6).</p><p>If you are not sure, talk to your doctor or nurse before you are given Tepkinly .</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor, pharmacist or nurse before using Tepkinly &nbsp;if you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have current or past problems with your nervous system &ndash; such as seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are due to have a vaccine or you know you may need to have one in the near future.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or nurse before you are given Tepkinly .</p><p>&nbsp;</p><p>Tell your doctor straight away if you get symptoms of any of the side effects listed below, during or after treatment with Tepkinly . You may need additional medical treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cytokine release syndrome &ndash; </strong>a life-threatening condition causing fever, vomiting, difficulty breathing/shortness of breath, chills, rapid heartbeat, headache and dizziness or light-headedness associated with medicines that stimulate T cells.</p><p>&minus; Before each injection under the skin, you may be given medicines which help reduce possible effects of cytokine release syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ICANS (immune effector cell-associated neurotoxicity syndrome)</strong>- Symptoms may include problems with use of language (including speech, understanding, writing and reading), drowsiness, confusion/disorientation, muscle weakness, seizures, swelling of a part of the brain, and memory loss.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections</strong> &ndash; you may get signs of infection, such as fever of 38&nbsp;&deg;C or above, chills, cough, or pain with urination which can vary depending on where in the body the infection is.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tumour lysis syndrome &ndash; </strong>some people may get unusual levels of some salts in the blood &ndash; caused by the fast breakdown of cancer cells during treatment. This is called tumour lysis syndrome (TLS).</p><p>o&nbsp;&nbsp; Your doctor or nurse will do blood tests to check for this condition. Before each injection under the skin, you should be well-hydrated and may be given other medicines that can help reduce high levels of uric acid and help reduce possible effects of tumour lysis syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tumour flare &ndash; </strong>as your cancer is destroyed, it may react and appear to get worse <strong>&ndash; </strong>this is called &lsquo;tumour flare reaction&rsquo;.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Tepkinly &nbsp;is not recommended in children and adolescents under 18&nbsp;years, as there is no information about use in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Tepkinly </strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking or using, have recently taken or used, or might take or use any other medicines. This includes medicines obtained without a prescription and herbal medicines.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p><strong>&nbsp;</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not use Tepkinly &nbsp;during pregnancy, as it may affect your unborn baby. Your doctor may ask you to take a pregnancy test before starting treatment.</p><p>&nbsp;</p><p><strong>Contraception</strong></p><p>&nbsp;</p><p>If you are a woman who is able to have children, you must use effective contraception to avoid becoming pregnant while taking Tepkinly &nbsp;and for at least 4&nbsp;months after your last dose of Tepkinly . If you become pregnant during this time, you must talk to your doctor straight away.</p><p>&nbsp;</p><p>Talk to your doctor or nurse about suitable methods of contraception.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>&nbsp;</p><p>You must not breast-feed during treatment with Tepkinly &nbsp;and for at least 4&nbsp;months after the last dose. It is not known whether Tepkinly &nbsp;passes into breast milk and whether it could affect your baby.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>&nbsp;</p><p>The effect of Tepkinly &nbsp;on male and female fertility is unknown.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Due to the possible symptoms of ICANS, you should be careful while driving, cycling or using heavy or potentially dangerous machines. If you currently have such symptoms, avoid these activities and contact your doctor, nurse, or pharmacist. See section 4 for more information about side effects.</p><p>&nbsp;</p><p><strong>Tepkinly &nbsp;contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p><strong>Tepkinly &nbsp;contains sorbitol</strong></p><p>&nbsp;</p><p>This medicine contains 21.9&nbsp;mg sorbitol in each vial, which is equivalent to 27.33&nbsp;mg/ml.</p><p><strong>Tepkinly contains polysorbate </strong></p><p>&nbsp;</p><p>This medicine contains 0.42&nbsp;mg of polysorbate 80 in each vial, equivalent to 0.4&nbsp;mg/ml. Polysorbate 80 may cause allergic reactions. Tell your doctor if you have any known allergies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A doctor experienced in treating cancer will take care of your treatment. Follow the treatment schedule explained to you by your doctor.</p><p>&nbsp;</p><p>Tepkinly &nbsp;will be given to you by a doctor or nurse as an injection under your skin.</p><p>Tepkinly &nbsp;will be given to you in cycles of 28&nbsp;days, on a dosing schedule given to you by your doctor.</p><p>&nbsp;</p><p>You will be given Tepkinly &nbsp;according to the following schedule</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Cycle</strong></p></td><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cycles 1 to 3</p></td><td style="vertical-align:top"><p>Weekly</p></td></tr><tr><td style="vertical-align:top"><p>Cycles 4 to 9</p></td><td style="vertical-align:top"><p>Every two weeks</p></td></tr><tr><td style="vertical-align:top"><p>Cycles 10 and beyond</p></td><td style="vertical-align:top"><p>Every four weeks</p></td></tr></tbody></table><p>&nbsp;</p><p>You may be given other medicines before you are given Tepkinly . This is to help prevent reactions such as cytokine release syndrome and fever in Cycle 1 (and potentially future cycles).</p><p>These medicines may include</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids &ndash; such as dexamethasone, prednisolone or equivalent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An antihistamine &ndash; such as diphenhydramine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paracetamol</p><p>&nbsp;</p><p><u>If you have </u>diffuse large B-cell lymphoma (<u>DLBCL)</u></p><p>The first full dose (48&nbsp;mg) of Tepkinly &nbsp;will be given to you on Cycle 1 Day 15. Your doctor will monitor how your treatment is working and ask you to stay in a hospital for 24&nbsp;hours after the first full dose (48&nbsp;mg) because this is when reactions such as CRS, ICANS and fever are most likely to happen.</p><p><u>&nbsp;</u></p><p><u>If you have </u>follicular lymphoma (FL)</p><p>The first full dose (48&nbsp;mg) of Tepkinly will be given to you on Cycle 1 Day 22.</p><p>&nbsp;</p><p>&nbsp;</p><p>You will be given Tepkinly &nbsp;for as long as your doctor thinks you are benefitting from the treatment.</p><p>&nbsp;</p><p>Your doctor may delay or completely stop your treatment with Tepkinly &nbsp;if you have certain side effects.</p><p><em>&nbsp;</em></p><p><strong>If you forget to use Tepkinly </strong></p><p>If you forget or miss your medical appointment, make another one straight away. For the treatment to be fully effective, it is very important not to miss a dose.</p><p>&nbsp;</p><p><strong>If you stop using Tepkinly </strong></p><p>Do not stop treatment with Tepkinly &nbsp;unless you have discussed this with your doctor. This is because stopping treatment may make your condition worse.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>&nbsp;</p><p>Tell your doctor straight away if you notice any of the symptoms of the following serious side effects. You may only get one or some of these symptoms.</p><p>&nbsp;</p><p><strong>Cytokine release syndrome (CRS) (Very common</strong>: may affect more than 1 in 10 people)</p><p>Symptoms can include</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness or light-headedness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing/shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&nbsp;</p><p><strong>Immune effector cell-associated neurotoxicity syndrome (ICANS) (</strong><strong>Common:</strong> may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effects on your nervous system, the symptoms of which can occur days or weeks after you receive the injection, may initially be subtle. Some of these symptoms may be signs of a serious immune reaction called &ldquo;immune effector cell-associated neurotoxicity syndrome&rdquo; (ICANS). Symptoms can include</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty speaking or writing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion/disorientation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; memory loss</p><p><strong>&nbsp;</strong></p><p><strong>Tumour lysis syndrome (TLS)</strong> (<strong>Common:</strong> may affect up to 1 in 10 people)</p><p>Symptoms can include</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark or cloudy urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle or joint pain&nbsp;</p><p>&nbsp;</p><p><strong>Other side effects </strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor or nurse straight away if you notice any of the following side effects or if they get worse:</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong>: may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; viral infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia (lung infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infections (infection of the airways)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased hunger</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in bones, joints, ligaments and muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the belly area</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling</p><p>&nbsp;</p><p>Shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of a type of white blood cells that fight infection (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of red blood cells, which can cause tiredness, pale skin, and shortness of breath (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of blood platelets, which can lead to bleeding and bruising (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in a type of white blood cell called a lymphocyte, that may affect the body&rsquo;s ability to fight infection (lymphopenia)</p><p>&nbsp;</p><p><strong>Common:</strong> may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever due to infection when you have low levels of white blood cells (febrile neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tender swollen lymph nodes, chest pain, cough or difficulty breathing, pain at the site of the tumour (tumour flare)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infections (caused by a type of germ called a fungus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening reaction the body has to an infection (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rapid breakdown of tumour cells resulting in chemical changes in the blood and damage to organs, including the kidneys, heart, and liver (tumour lysis syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; extra fluid around the lungs that can make it difficult to breathe (pleural effusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&nbsp;</p><p>Shown in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of phosphates in the blood, potassium, magnesium or sodium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of creatinine, a breakdown product from muscle tissue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of liver proteins, which may show problems with the liver</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tepkinly &nbsp;will be stored by the doctor, nurse, or pharmacist at the hospital or clinic. To correctly store Tepkinly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store and transport refrigerated (2&nbsp;&deg;C to 8&nbsp;&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the vial in the outer carton in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tepkinly &nbsp;4&nbsp;mg/0.8&nbsp;ml is a solution &nbsp;which may be diluted prior to use.</p><p>o&nbsp;&nbsp; <strong>Dilute prior to subcutaneous use for 0.16&nbsp;mg and 0.8&nbsp;mg doses. </strong></p><p>o&nbsp;&nbsp; <strong>No dilution required for 3 mg dose.</strong></p><p>o&nbsp;&nbsp; <strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not used immediately, the prepared solution may be stored for up to 24&nbsp;hours at 2&nbsp;&deg;C to 8&nbsp;&deg;C from the time of preparation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Within these 24&nbsp;hours, the prepared solution can be stored for up to 12&nbsp;hours at room temperature (20&nbsp;&deg;C - 25&nbsp;&deg;C) from the start of dose preparation to administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow the solution to warm to room temperature before using.</p><p>&nbsp;</p><p>Your doctor, nurse or pharmacist will throw away any unused medicine following local requirements. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Tepkinly &nbsp;contains </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is epcoritamab. Each 0.8&nbsp;ml vial contains 4&nbsp;mg of epcoritamab at a concentration of 5&nbsp;mg/ml.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are sodium acetate trihydrate, acetic acid, sorbitol (E420), polysorbate 80, water for injections (see section 2 &ldquo;Tepkinly &nbsp;contains sodium&rdquo; and &ldquo;Tepkinly &nbsp;contains sorbitol&rdquo;).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tepkinly  is a solution for injection. It is a colourless to slightly yellow solution provided in a glass vial.

Each carton contains 1 vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Vetter Pharma-Fertigung</p><p>GmbH &amp; Co. KG</p><p>Eisenbahnstrasse 2-4</p><p>88085 Langenargen, Germany</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder </strong></p><p><strong>&nbsp;</strong></p><p>AbbVie Deutschland GmbH &amp; Co. KG</p><p>Knollstrasse</p><p>67061 Ludwigshafen</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	July 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تبكنلي هو دواء للسرطان يحتوي على المادة الفعالة إبكوريتاماب. تبكنلي يستخدم بمفرده (علاج وحيد) لعلاج المرضى البالغين المصابين بسرطان الدم الذي يُسمى لمفوما الخلايا البائية الكبيرة المنتشرة (DLBCL) أو اللمفوما الجريبية عند معاودة المرض أو عدم استجابته للعلاج السابق بعد علاجَيْن سابقَيْن على الأقلّ.</p><p>&nbsp;</p><p dir="RTL"><strong>كيف يعمل تبكنلي </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إبكوريتاماب مصمم بشكل خاص لمساعدة جهازك المناعي على مهاجمة الخلايا السرطانية (سرطان الغدد الليمفاوية). يعمل إبكوريتاماب عن طريق الارتباط بالخلايا المناعية في الجسم والخلايا السرطانية، وجمعها معًا، حتى يتمكن جهازك المناعي من تدمير الخلايا السرطانية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل </strong><strong>تبكنلي </strong></p><p>&nbsp;</p><p dir="RTL">إذا كنت تعاني من حساسية تجاه إبكوريتاماب أو أي من مكونات هذا الدواء الأخرى (المذكورة في القسم ٦).</p><p dir="RTL">إذا لم تكن متأكدا، فتحدّث إلى طبيبك، الصيدلاني أو الممرضة قبل أن تُعطى تبكنلي.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p>&nbsp;</p><p dir="RTL">تحدّث إلى طبيبك، الصيدلاني أو الممرضة قبل استعمال تبكنلي إذا كنت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصابا بمشاكل في الوقت الحالي أو من قبل في جهازك العصبي - كالنوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مصابا بحالة عدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على وشك تلقي لقاح أو تعلم أنك قد تحتاج لتلقي لقاح في المستقبل القريب.</p><p>&nbsp;</p><p dir="RTL">إذا كان أي مما ذكر أعلاه ينطبق عليك (أو إذا كنت غير متأكد)، فتحدث إلى طبيبك أو الصيدلاني قبل أن تُعطى تبكنلي.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا أصبت بأعراض أي من التأثيرات الجانبية المذكورة أدناه، في اثناء العلاج بواسطة تبكنلي أو بعده، فربما كنت بحاجة لعلاج طبي إضافي. ستجد سردا لأعراض كل التأثيرات الجانبية في القسم ٤.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة إطلاق السيتوكين- </strong>حالة مهددة للحياة تسبب الحمى والقيء وصعوبة التنفس/ضيق التنفس والقشعريرة وسرعة ضربات القلب والصداع والدوخة أو الدوار الخفيف المرتبط بالأدوية التي تحفز الخلايا التائية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل كل حقنة تحت الجلد، قد يتم إعطاؤك أدوية تساعد في تقليل التأثيرات المحتملة لمتلازمة إطلاق السيتوكين.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>متلازمة السميّة العصبية المرافقة لخلية مناعية مستفعِلة (</strong><strong>ICANS</strong><strong>)- </strong>قد تشمل الأعراض مشاكل في استخدام اللغة (بما في <strong>ذلك الكلام والفهم والكتابة والقراءة)، والنعاس، والارتباك / التوهان، وضعف العضلات، والنوبات، وتورم جزء من الدماغ، وفقدان الذاكرة.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>حالات العدوى- </strong>قد تصاب بعلامات العدوى، مثل: حمى تصل إلى 38 درجة مئوية أو أعلى، أو قشعريرة، أو سعال، أو ألم عند التبول والتي قد تختلف استنادا إلى مكان حدوث العدوى في الجسم.</p><p dir="RTL"><strong><em>&nbsp;</em></strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة انحلال الورم - &nbsp;</strong>قد يحصل بعض الأشخاص على مستويات غير عادية من بعض الأملاح في الدم- بسبب التحلل السريع للخلايا السرطانية أثناء العلاج. وهذا ما يسمى متلازمة انحلال الورم (TLS).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك أو الممرضة بإجراء اختبارات الدم للتحقق من هذه الحالة. قبل كل حقنة تحت الجلد، يجب أن تكون رطبًا جيدًا وقد يتم إعطاؤك أدوية أخرى يمكن أن تساعد في تقليل المستويات المرتفعة من حمض اليوريك وتساعدفي تقليل التأثيرات المحتملة لمتلازمة انحلال الورم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>توهج الورم</strong> - مع تدمير السرطان، قد يتفاعل ويبدو أنه يزداد سوءًا - وهذا ما يسمى &quot;رد فعل توهج الورم&quot;.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p>&nbsp;</p><p dir="RTL">لا يوصى باستعمال تبكنلي للأطفال والمراهقين الذين لم يبلغوا الثامنة عشرة من العمر، نظرا لعدم توفر معلومات عن استعماله لهذه الفئة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وتبكنلي</strong></p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلاني إذا كنت تتناول أو تستعمل حالياً، تناولت أو استعملت مؤخّراً، أو قد تتناول أو تستعمل أي دواء آخر. وهذا يتضمن الأدوية التي يمكن الحصول عليها دون وصفة طبية والأدوية العشبية.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل</strong><strong> </strong></p><p>&nbsp;</p><p dir="RTL">إذا كنت حاملا أو مرضعا، أو تعتقدين بأنك حامل أو تخططين للإنجاب، فاطلبي نصيحة طبيبك أو الصيدلاني قبل تلقّي هذا الدواء. لا تستعملي تبكنلي في أثناء الحمل، نظرا لأنه قد يؤثر على طفلك الذي لم يولد بعد. قد يطلب منك طبيبك إجراء اختبار الحمل قبل بدء العلاج.</p><p>&nbsp;</p><p dir="RTL"><strong>منع الحمل</strong></p><p>&nbsp;</p><p dir="RTL">إذا كنتِ امرأة قادرة على الإنجاب، فيجب أن تستعملي وسيلة فعالة لمنع الحمل لتتجنبي الحمل في أثناء تلقّي تبكنلي ولمدة 4 أشهر على الأقل بعد تلقّي آخر جرعة من تبكنلي. إذا أصبحت حاملا في هذه الفترة، فيجب أن تُعلمي طبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL">تحدثي إلى طبيبك أو الممرضة عن الطرق المناسبة لمنع الحمل.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإرضاع</strong></p><p>&nbsp;</p><p dir="RTL">يجب أن تمتنعي عن إرضاع طفلك رضاعة طبيعية أثناء العلاج بوساطة تبكنلي ولمدة ٦ أشهر على الأقل بعد تلقي آخر جرعة منه. من غير المعروف ما إذا كان تبكنلي ينتقل إلى حليب الثدي ويؤثر بالتالي على طفلك.</p><p>&nbsp;</p><p dir="RTL"><strong>الخصوبة</strong></p><p>&nbsp;</p><p dir="RTL">إن تأثير تبكنلي على خصوبة الذكور والإناث غير معروف.</p><p>&nbsp;</p><p dir="RTL"><strong>قيادة السيارات واستعمال الآليات</strong></p><p>&nbsp;</p><p dir="RTL">نظرا لإمكانية حدوث متلازمة السميّة العصبية المرافقة لخلية مناعية مستفعلة (ICANS)، يجب أن تكون حذرا في أثناء القيادة، أو استعمال الدراجة أو استعمال الآليات الثقيلة أو تلك التي قد ينطوي استعمالها على خطر. إذا كنت مصابا في الوقت الحالي بأي أعراض كهذه، فيجب أن تتجنب هذه النشاطات وتتصل بطبيبك، أو الممرضة، أو الصيدلاني. راجع القسم ٤ للاطلاع على مزيد من المعلومات عن التأثيرات الجانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي تبكنلي على الصوديوم</strong></p><p>&nbsp;</p><p dir="RTL">هذا الدواء يحتوي على أقل من ١ ميلي مول من الصوديوم (٢٣ ملغ) في كل زجاجة، أي يمكن اعتبار أنه &rsquo;خالٍ من الصوديوم&lsquo; .</p><p>&nbsp;</p><p dir="RTL"><strong>تبكنلي يحتوي على السوربيتول</strong></p><p dir="RTL">يحتوي هذا الدواء على ٢١,٩ ملغ من السوربيتول في كل زجاجة، وهو ما يكافئ ٢٧,٣٣ ملغ/مل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تبكنلي يحتوي على </strong><strong>بوليسوربات</strong></p><p dir="RTL">يحتوي هذا الدواء على 0.42 من بوليسوربات 80 في كل زجاجة وهو ما يكافئ 0.4 ملغ/مل. بوليسوربات 80 قد يسبب ردة فعل تحسسية. أخبر طبيبك إذا كانت لديك حساسية معروفة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتولى طبيب خبير بعلاج السرطان أمر علاجك. اتبع برنامج العلاج الذي شرحه لك طبيبك.</p><p dir="RTL">ستُعطى تبكنلي من قبل طبيب أو ممرضة وسيُعطى لك كحقنة تحت الجلد.</p><p dir="RTL">ستُعطى تبكنلي بدورات علاجية مدة كل منها ٢٨ يوما، وفق جدول جرعات يعطيك إياه طبيبك.</p><p>&nbsp;</p><p dir="RTL">ستُعطى تبكنلي استنادا إلى الجدول التالي</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الدورة</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>جدول الجرعات</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الدورات ١ إلى ٣</p></td><td style="vertical-align:top"><p dir="RTL">أسبوعيا</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الدورات ٤ إلى ٩</p></td><td style="vertical-align:top"><p dir="RTL">كل أسبوعين</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الدورات ١٠ وما بعدها</p></td><td style="vertical-align:top"><p dir="RTL">كل ٤ أسابيع</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">قد تُعطى أدوية أخرى قبل أن تٌعطى تبكنلي. وهذا للمساعدة على الوقاية من التفاعلات كمتلازمة إطلاق السيتوكين وارتفاع الحرارة في الدورة العلاجية ١ (وفي الدورات القادمة المحتملة).&nbsp;</p><p dir="RTL">قد تشمل هذه الأدوية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات- مثل الديكساميثازون, البردنيزولون أو ما يكافئه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد مضادات الهستامين- مثل دايفنهيدرامين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; باراسيتامول</p><p dir="RTL">&nbsp;</p><p><u>إذا كنت تعاني من لمفوما الخلايا البائية الكبيرة المنتشرة:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ستُعطى لك الجرعة الأولى الكاملة (٤٨ ملغ) من تبكنلي في اليوم ١٥ من&nbsp; الدورة العلاجية ١. سيقوم طبيبك بمراقبة كيفية عمل علاجك ويطلب منك البقاء في المستشفى لمدة ٢٤ ساعة على الأقل بعد الجرعة الأولى الكاملة (٤٨ ملغ) لأن هذا هو الوقت الذي من المرجح أن تحدث فيه تفاعلات مثل متلازمة إطلاق السيروتونين (CRS) و متلازمة السميّة العصبية المرافقة لخلية مناعية مستفعِلة (ICANS) والحمى.</p><p dir="RTL"><br /><u>إذا كنت تعاني من اللمفوما الجريبية:</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">ستعطى إليك الجلاعة الأولى الكاملة (48 ملغ) في اليوم 22 من الدورة العلاجية 1.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ستُعطى تبكنلي طالما رأى طبيبك أنك تستفيد من العلاج.</p><p>&nbsp;</p><p dir="RTL">قد يؤجل طبيبك علاجك بواسطة تبكنلي أو يوقفه نهائيا إذا أصبت بتأثيرات جانبية مؤكدة.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>إذا نسيت أن تستعمل تبكنلي</strong></p><p dir="RTL">إذا نسيت موعد طبي أو فاتك حضوره، فحدد موعدا آخر على الفور. لكي تكون المعالجة فعالة تماما، من المهم جدا ألا تفوّت جرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استعمال تبكنلي</strong></p><p dir="RTL">لا توقف العلاج بواسطة تبكنلي إلا إذا ناقشت هذا الأمر مع طبيبك. وهذا لأن إيقاف العلاج قد يسبب تدهور حالتك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بخصوص استعمال هذا الدواء، فاسأل طبيبك، الصيدلاني أو الممرضة.&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هي الحال مع كافة الأدوية، من الممكن أن يسبب هذا الدواء تأثيرات جانبية، رغم أنها لا تصيب كافة الأشخاص.</p><p>&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الخطيرة</strong></p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت حدوث أعراض أي من التأثيرات الجانبية الخطيرة التالية.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">قد تصاب بواحد أو أكثر من هذه الأعراض.</p><p>&nbsp;</p><p dir="RTL"><strong>متلازمة إطلاق السيروتونين (</strong><strong>CRS</strong><strong>) (شائعة جدا</strong> (قد تصيب أكثر من ١ من ١٠ أشخاص)</p><p dir="RTL">من الممكن أن تشمل أعراضها:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب سريعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة / ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدلات الأكسجين في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p>&nbsp;</p><p dir="RTL"><strong>متلازمة السميّة العصبية المرافقة لخلية مناعية مستفعِلة (</strong><strong>ICANS</strong><strong>) (شائعة: </strong>قد تصيب حتى ١ من ١٠ أشخاص)<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات على الجهاز العصبي، من الممكن أن تحدث أعراضها بعد أيام أو أسابيع من تلقّي الحقنة، وقد تكون خفيّة في البداية. قد تكون بعض هذه الأعراض علامات لتفاعل مناعي خطير يطلق عليه اسم &quot;متلازمة السميّة العصبية المرافقة لخلية مناعية مستفعِلة&quot; (ICANS). من الممكن أن تشمل أعراض متلازمة السميّة العصبية المرافقة لخلية مناعية مستفعِلة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التكلم أو الكتابة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك / توهان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقد الذاكرة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>متلازمة انحلال الورم</strong><strong>&nbsp; </strong><strong>(</strong><strong>TLS</strong><strong>) </strong><strong>(شائعة: </strong>قد تصيب حتى ١ من ١٠ أشخاص)</p><p dir="RTL">الأعراض قد تشمل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول الداكن أو الغائم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب غير معتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات أو المفاصل</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>التأثيرات الجانبية الأخرى</strong></p><p dir="RTL">أخبر طبيبك أو الممرض على الفور إذا لاحظت أيًا من الآثار الجانبية التالية أو إذا تفاقمت:</p><p dir="RTL"><strong>&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>شائعة جدا:</strong> قد تصيب أكثر من ١ من ١٠ أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فيروسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي (عدوى الرئة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التنفسي العلوي (عدوى الشعب الهوائية)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الجوع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العظام والمفاصل والأربطة والعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم</p><p>&nbsp;</p><p dir="RTL"><strong>تأثيرات تظهر في اختبارات الدم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدلات نوع من خلايا الدم البيضاء التي تحارب العدوى(قلة العَدِلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل خلايا الدم الحمراء، مما قد يسبب التعب (فقر الدم) وشحوب الجلد وضيق التنفس (فقر الدم) &nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفيحات الدموية، وهو ما قد يجعلك أكثر عرضة للإصابة بالكدمات أو النزف (قلة الصفيحات)&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في نوع من خلايا الدم البيضاء تسمى الخلايا الليمفاوية، مما قد يؤثر على قدرة الجسم على مكافحة العدوى (قلة اللمفاويات</p><p dir="RTL"><em>&nbsp;</em></p><p>&nbsp;</p><p dir="RTL"><strong>شائعة:</strong> قد تصيب حتى ١ من ١٠ أشخاص</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى بسبب العدوى عندما يكون لديك مستويات منخفضة من خلايا الدم البيضاء (قلة العدلات الحموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم العقد الليمفاوية، وألم في الصدر، وسعال أو صعوبة في التنفس، وألم في مكان الورم (توهج الورم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهابات الفطرية (التي يسببها نوع من الجراثيم تسمى الفطريات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل الجسم المهدد للحياة تجاه العدوى (الإنتان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحلّل سريع للخلايا الورمية يؤدي إلى تغيرات كيميائية في الدم وتأذي الأعضاء، بما فيها الكليتين، القلب، والكبد (متلازمة انحلال الورم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السوائل حول الرئتين مما قد يجعل التنفس صعبًا (الانصباب الجنبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثيرات تظهر في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الفوسفات في الدم، البوتاسيوم، المغنيسيوم أو الصوديوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الكرياتينين في الدم، وهو منتج تحلل الأنسجة العضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى بروتينات الكبد في الدم، مما قد يدل على وجود مشاكل في الكبد</p><p dir="RTL"><strong>الابلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير متكررة في هذه النشرة، فضلًا أبلغ الطبيب أو مقدم الرعاية الصحية أو الصيدلي. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيُحفظ تبكنلي من قبل الطبيب، الممرضة أو الصيدلاني في المستشفى أو العيادة. لحفظ تبكنلي بطريقة سليمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحتفظ بهذا الدواء بعيدا عن مرأى الأطفال ومتناول أيديهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء بعد انقضاء تاريخ الصلاحية المبيّن على لصاقة الزجاجة والكرتونة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظه وانقله مبرّدا (٢ إلى ٨ درجات مئوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تجمده.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالزجاجة ضمن عبوتها الخارجية لتحميها من الضوء. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبكنلي ٤ ملغ/٠,٨ مل محلول &nbsp;من الممكن تخفيفه قبل الاستعمال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تخفيف المحلول للجرعات 0.16 و 0.8 ملغ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحتاج الجرعة 3 ملغ إلى تخفيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال عدم استعماله على الفور، يمكن حفظ المحلول المعدّ لمدة تصل إلى ٢٤ ساعة ضمن درجة حرارة تتراوح بين ٢ و ٨ درجات مئوية بدءًا من وقت إعداده.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلال هذه الـ ٢٤ ساعة، يمكن حفظ محلول إبكوريتاماب ضمن درجة حرارة الغرفة (20 إلى 25 درجات مئوية) لمدة ١٢ ساعة تبدأ من تحضير الجرعة وحتى إعطائها.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسمح للمحلول أن يدفأ ليصبح على درجة حرارة الغرفة قبل استعماله. &nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">سيعمد الطبيب، الممرضة أو الصيدلاني إلى التخلص من أي كمية غير مستعملة من الدواء مع الالتزام بالمتطلبات المحلية. هذه الإجراءات تساعد على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي مكوّنات تبكنلي </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي إبكوريتاماب. &nbsp;تحتوي كل زجاجة سعة 0.8 مل على 4 ملغ من إبكوريتاماب بتركيز 5 ملغ لكل مل</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسوغة الأخرى هي أسيتات الصوديوم ثلاثي الهيدرات، حمض الخلّ، سوربيتول (E420)، بولي سوربات ٨٠، ماء للحقن (راجع القسم ٢ &quot;يحتوي تبكنلي على الصوديوم&quot; و&quot;يحتوي تبكنلي على السوربيتول&quot;).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو تبكنلي ومحتويات العبوة</strong></p><p>&nbsp;</p><p dir="RTL">تبكنلي هو محلول للحقن عديم اللون أو ضارب للصفرة مقدم في زجاجة .</p><p>&nbsp;</p><p dir="RTL">تحتوي كل كرتونة على زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنّعة:</strong></p><p dir="RTL">فيتر فارما &ndash; فيرتيغنغ جي إم بي إتش</p><p dir="RTL">وشركاه كي جي</p><p dir="RTL">ايزنبانستراس 4-2</p><p dir="RTL">99085 لانغنارغن. المانيا</p><p>&nbsp;</p><p dir="RTL"><strong>حامل رخصة التسويق</strong><strong>:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">آبفي دويتشلند جي أم بي إتش وشركاه كي جي</p><p dir="RTL">نولستراز(س)</p><p dir="RTL">٦٧٠٦١ لودفيكسهافن</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في يوليو 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tepkinly 4 mg/0.8 ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 0.8 ml vial contains 4 mg of epcoritamab at a concentration of 5 mg/ml.

Each vial contains an overfill that allows withdrawal of the labelled amount.

Epcoritamab is a humanised immunoglobulin G1 (IgG1) bispecific antibody against CD3 and CD20 antigens, produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

Excipient with known effect
Each vial of Tepkinly contains 21.9 mg of sorbitol and 0.42 mg of polysorbate 80. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection)

Colourless to slightly yellow solution, pH 5.5 and osmolality of approximately 211 mOsm/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.</p><p>&nbsp;</p><p>Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.</p><p><strong>&nbsp;</strong></p><p>These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tepkinly must only be administered under the supervision of a healthcare professional qualified in the use of anti-cancer therapy. At least 1 dose of tocilizumab for use in the event of CRS should be available prior to epcoritamab administration for Cycle 1. Access to an additional dose of tocilizumab within 8&nbsp;hours of use of the previous tocilizumab dose should be available.</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><em>Recommended pre-medication and dose schedule</em></p><p><u>&nbsp;</u></p><p>Tepkinly should be administered according to the following step-up dose schedule in 28‑day cycles which is outlined in Table 1 for patients with diffuse large B-cell lymphoma and Table 2 for patients with follicular lymphoma.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 1 Tepkinly 2-step step-up dose schedule for patients with d</strong><strong>iffuse large B-cell lymphoma</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:582px"><thead><tr><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:top"><p><strong>Cycle of treatment</strong></p></td><td style="vertical-align:top"><p><strong>Days</strong></p></td><td style="vertical-align:top"><p><strong>Epcoritamab dose (mg)<sup>a</sup></strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Weekly</p></td><td rowspan="4" style="vertical-align:top"><p>Cycle 1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.16&nbsp;mg (Step-up dose 1)</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.8&nbsp;mg (Step-up dose 2)</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>48&nbsp;mg (First full dose)</p></td></tr><tr><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Weekly</p></td><td style="vertical-align:top"><p>Cycles 2 - 3</p></td><td style="vertical-align:top"><p>1, 8, 15, 22</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Every two weeks</p></td><td style="vertical-align:top"><p>Cycles 4 - 9</p></td><td style="vertical-align:top"><p>1, 15</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Every four weeks</p></td><td style="vertical-align:top"><p>Cycles 10 +</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>0.16&nbsp;mg is a priming dose, 0.8&nbsp;mg is an intermediate dose and 48&nbsp;mg is a full dose.</p></td></tr></thead></table><p>&nbsp;</p><p><strong>Table 2 Tepkinly 3-step step-up dose </strong><strong>schedule for patients with follicular lymphoma</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:582px"><thead><tr><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:top"><p><strong>Cycle of treatment</strong></p></td><td style="vertical-align:top"><p><strong>Days</strong></p></td><td style="vertical-align:top"><p><strong>Epcoritamab dose (mg)<sup>a</sup></strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Weekly</p></td><td rowspan="4" style="vertical-align:top"><p>Cycle 1</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.16&nbsp;mg (Step-up dose 1)</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>0.8&nbsp;mg (Step-up dose 2)</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>3&nbsp;mg (Step-up dose 3)</p></td></tr><tr><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>48&nbsp;mg (First full dose)</p></td></tr><tr><td style="vertical-align:top"><p>Weekly</p></td><td style="vertical-align:top"><p>Cycles 2 - 3</p></td><td style="vertical-align:top"><p>1, 8, 15, 22</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Every two weeks</p></td><td style="vertical-align:top"><p>Cycles 4 - 9</p></td><td style="vertical-align:top"><p>1, 15</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>Every four weeks</p></td><td style="vertical-align:top"><p>Cycles 10 +</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>48&nbsp;mg</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>0.16&nbsp;mg is a priming dose, 0.8&nbsp;mg is an intermediate dose, 3&nbsp;mg is a second intermediate dose and 48&nbsp;mg is a full dose.</p></td></tr></thead></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Tepkinly should be administered until disease progression or unacceptable toxicity.</p><p><u>&nbsp;</u></p><p>Details on recommended pre-medication for cytokine release syndrome (CRS) are shown in Table 3.</p><p>&nbsp;</p><p><strong>Table 3 Epcoritamab pre-medication </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p><strong>Cycle</strong></p></td><td style="vertical-align:top"><p><strong>Patient requiring pre-medication</strong></p></td><td style="vertical-align:top"><p><strong>Pre-medication</strong></p></td><td style="vertical-align:top"><p><strong>Administration </strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cycle 1</strong></p></td><td rowspan="2" style="vertical-align:top"><p>All patients&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Dexamethasone<sup>b</sup><sup> </sup>(15&nbsp;mg oral or intravenous) or Prednisolone (100&nbsp;mg oral or intravenous) or equivalent&nbsp;&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30-120&nbsp;minutes prior to each weekly administration of epcoritamab&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; And for three consecutive days following each weekly administration of epcoritamab in Cycle 1</p></td></tr><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diphenhydramine</p><p>(50&nbsp;mg oral or intravenous) or equivalent</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paracetamol</p><p>(650 to 1&nbsp;000&nbsp;mg oral)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30-120&nbsp;minutes prior to each weekly administration of epcoritamab&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cycle 2 and beyond</strong></p></td><td style="vertical-align:top"><p>Patients who experienced Grade 2 or 3<sup>a</sup> CRS with previous dose&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>Dexamethasone<sup>b</sup> (15&nbsp;mg oral or intravenous) or Prednisolone (100&nbsp;mg oral or intravenous) or equivalent&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30-120&nbsp;minutes prior to next administration of epcoritamab after a grade</p><p>2 or 3<sup>a</sup> CRS event</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; And for three consecutive days following the next administration of epcoritamab until epcoritamab is given without subsequent any grade of CRS</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>Patients will be permanently discontinued from epcoritamab after a Grade 4 CRS event.</p><p><sup>b</sup>Dexamethasone is the preferred corticosteroid for CRS prophylaxis based on the GCT3013-01 Optimisation study.</p></td></tr></tbody></table><p>&nbsp;</p><p>Prophylaxis against <em>Pneumocystisjirovecii</em> pneumonia (PCP) and herpes virus infections is strongly recommended especially during concurrent use of steroids.</p><p>&nbsp;</p><p>Tepkinly should be administered to adequately hydrated patients.</p><p>&nbsp;</p><p>It is strongly recommended that all patients adhere to the following fluid guidelines during Cycle 1, unless medically contraindicated:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2-3&nbsp;L of fluid intake during the 24 hours prior to each epcoritamab administration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold antihypertensive medications for 24 hours prior to each epcoritamab administration</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer 500&nbsp;ml isotonic intravenous (IV) fluids on the day of epcoritamab prior to dose administration; AND</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2-3&nbsp;L of fluid intake during the 24 hours following each epcoritamab administration.</p><p>&nbsp;</p><p>Patients at an increased risk for clinical tumour lysis syndrome (CTLS) are recommended to receive hydration and prophylactic treatment with a uric acid lowering agent.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of CRS and/or immune effector cell-associated neurotoxicity syndrome (ICANS) and managed per current practice guidelines following epcoritamab administration. Patients should be counselled on the signs and symptoms associated with CRS and ICANS and on seeking immediate medical attention should signs or symptoms occur at any time (see section 4.4).</p><p>&nbsp;</p><p>Patients with DLBCL should be hospitalised for 24&nbsp;hours after administration of the Cycle 1 Day 15 dose of 48&nbsp;mg to monitor for signs and symptoms of CRS and/or ICANS.</p><p>&nbsp;</p><p><u>Dose modifications and management of adverse reactions </u></p><p><em>&nbsp;</em></p><p><em>Cytokine release syndrome (CRS)</em></p><p>Patients treated with epcoritamab may develop CRS.</p><p>Evaluate for and treat other causes of fever, hypoxia, and hypotension. If CRS is suspected, manage according to the recommendations in Table 4. Patients who experience CRS should be monitored more frequently during next scheduled epcoritamab administration.</p><p>&nbsp;</p><p><strong>Table 4 CRS grading and management guidance</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><thead><tr><td style="vertical-align:top"><p><strong>Grade<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Recommended therapy</strong></p></td><td style="vertical-align:top"><p><strong>Epcoritamab dose modification</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Grade 1</strong></p><p>&bull; Fever (temperature &ge;&nbsp;38&nbsp;&deg;C)</p></td><td style="vertical-align:top"><p>Provide supportive care such as antipyretics and</p><p>intravenous hydration</p><p><strong>&nbsp;</strong></p><p>Dexamethasone<sup>b</sup> may be initiated</p><p><strong>&nbsp;</strong></p><p>In cases of advanced age, high tumour burden, circulating tumour cells, fever refractory to antipyretics</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti‑cytokine therapy, tocilizumab<sup>d</sup>, should be considered</p><p>For CRS with concurrent ICANS refer to <strong>Table 5</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hold epcoritamab until resolution of CRS event</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2</strong></p><p>&bull; Fever (temperature &ge;&nbsp;38&nbsp;&deg;C)</p><p><strong>&nbsp;</strong></p><p>and</p><p><strong>&nbsp;</strong></p><p>&bull; Hypotension not requiring vasopressors</p><p><strong>&nbsp;</strong></p><p>and/or</p><p><strong>&nbsp;</strong></p><p>&bull; Hypoxia requiring low-flow oxygen<sup>e</sup> by nasal cannula or blow-by</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Provide supportive care such as antipyretics and</p><p>intravenous hydration</p><p><strong>&nbsp;</strong></p><p>Dexamethasone<sup>b</sup> should be considered</p><p>&nbsp;</p><p>Anti‑cytokine therapy,</p><p>tocilizumab<sup>d</sup>, is recommended</p><p><strong>&nbsp;</strong></p><p>If CRS is refractory to dexamethasone and tocilizumab:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternative immunosuppressants<sup>g</sup> and methylprednisolone 1&nbsp;000&nbsp;mg/day intravenously should be administered until clinical improvement</p><p>For CRS with concurrent ICANS refer to <strong>Table 5</strong></p></td><td style="vertical-align:top"><p>Hold epcoritamab until resolution of CRS event</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p><p>&bull; Fever (temperature &ge;&nbsp;38&nbsp;&deg;C)</p><p><strong>&nbsp;</strong></p><p>and</p><p><strong>&nbsp;</strong></p><p>&bull; Hypotension requiring a vasopressor with or without vasopressin</p><p><strong>&nbsp;</strong></p><p>and/or</p><p><strong>&nbsp;</strong></p><p>&bull; Hypoxia requiring high-flow oxygen<sup>f</sup> by nasal cannula, facemask, non‑rebreather mask, or venturi mask</p></td><td style="vertical-align:top"><p>Provide supportive care such as antipyretics and</p><p>intravenous hydration</p><p>&nbsp;</p><p>Dexamethasone<sup>c</sup> should be administered</p><p>&nbsp;</p><p>Anti‑cytokine therapy,</p><p>tocilizumab<sup>d</sup>, is recommended</p><p><strong>&nbsp;</strong></p><p>If CRS is refractory to dexamethasone and tocilizumab:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternative immunosuppressants<sup>g</sup> and methylprednisolone 1&nbsp;000&nbsp;mg/day intravenously should be administered until clinical improvement</p><p>&nbsp;</p><p>For CRS with concurrent ICANS refer to <strong>Table 5</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hold epcoritamab until resolution of CRS event</p><p>&nbsp;</p><p>In the event of Grade 3 CRS lasting longer than 72&nbsp;hours, epcoritamab should be discontinued</p><p>&nbsp;</p><p>If more than 2 separate events of Grade 3 CRS, even if each event resolved to Grade 2 within 72&nbsp;hours, epcoritamab should be discontinued</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 4</strong></p><p>&bull; Fever (temperature &ge;&nbsp;38&nbsp;&deg;C)</p><p><strong>&nbsp;</strong></p><p>and</p><p><strong>&nbsp;</strong></p><p>&bull; Hypotension requiring &ge;&nbsp;2&nbsp;vasopressors (excluding vasopressin)</p><p><strong>&nbsp;</strong></p><p>and/or</p><p><strong>&nbsp;</strong></p><p>&bull; Hypoxia requiring positive pressure ventilation (e.g., CPAP, BiPAP, intubation and mechanical ventilation<strong>)</strong></p></td><td style="vertical-align:top"><p>Provide supportive care such as antipyretics and</p><p>intravenous hydration</p><p><strong>&nbsp;</strong></p><p>Dexamethasone<sup>c</sup> should be administered</p><p>&nbsp;</p><p>Anti‑cytokine therapy,</p><p>tocilizumab<sup>d</sup>, is recommended</p><p>&nbsp;</p><p>If CRS is refractory to dexamethasone and tocilizumab:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternative immunosuppressants<sup>g</sup> and methylprednisolone 1&nbsp;000&nbsp;mg/day intravenously should be administered until clinical improvement</p><p>&nbsp;</p><p>For CRS with concurrent ICANS refer to <strong>Table 5</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Permanently discontinue epcoritamab</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>CRS graded according to ASTCT consensus criteria</p><p><sup>b</sup>Dexamethasone should be administered at 10-20&nbsp;mg per day (or equivalent)</p><p><sup>c</sup>Dexamethasone should be administered at 10-20&nbsp;mg intravenously every 6&nbsp;hours</p><p><sup>d</sup>Tocilizumab 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg per dose). Repeat tocilizumab after at least 8&nbsp;hours as needed. Maximum of 2&nbsp;doses in a 24-hour period</p><p><sup>e</sup>Low-flow oxygen is defined as oxygen delivered at &lt;&nbsp;6&nbsp;L/minute</p><p><sup>f</sup>High-flow oxygen is defined as oxygen delivered at &ge;&nbsp;6&nbsp;L/minute</p><p><sup>g</sup>Riegler L et al. (2019)</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em>Immune effector cell-associated neurotoxicity syndrome (ICANS)</em></p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of ICANS. Other causes of neurologic symptoms should be ruled out. If ICANS is suspected, manage according to the recommendations in Table 5.</p><p>&nbsp;</p><p><strong>Table 5 ICANS grading and management guidance</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><thead><tr><td style="vertical-align:top"><p><strong>Grade<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Recommended therapy</strong></p><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong>Epcoritamab dose modification</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Grade 1<sup>b</sup></strong></p><p>ICE score<sup>c</sup> 7-9<sup> b</sup></p><p>or, depressed level of</p><p>consciousness<sup>b</sup>: awakens</p><p>spontaneously</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Treatment with dexamethasone<sup>d</sup></p><p>&nbsp;</p><p>Consider non-sedating anti-seizure medicinal products (e.g., levetiracetam) until resolution of ICANS</p><p><strong>&nbsp;</strong></p><p>No concurrent CRS:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti‑cytokine therapy not recommended</p><p>&nbsp;</p><p>For ICANS with<em> </em>concurrent CRS:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with dexamethasone<sup>d</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose immunosuppressant alternatives<sup>e</sup> to tocilizumab, if possible</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hold epcoritamab until resolution of event</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 2<sup>b</sup></strong></p><p>ICE score<sup>c</sup> 3-6</p><p>or, depressed level of</p><p>consciousness<sup>b</sup>: awakens</p><p>to voice</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Treatment with dexamethasone<sup>f</sup></p><p>&nbsp;</p><p>Consider non-sedating anti-seizure medicinal products (e.g., levetiracetam) until resolution of ICANS</p><p>&nbsp;</p><p>No concurrent CRS<em>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti‑cytokine therapy not recommended</p><p>&nbsp;</p><p>For ICANS with concurrent CRS<em>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with dexamethasone<sup>d</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose immunosuppressant alternatives<sup>e</sup> to tocilizumab, if possible</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hold epcoritamab until resolution of event</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3<sup>b</sup></strong></p><p>ICE score<sup>c</sup> 0-2</p><p>or, depressed level of</p><p>consciousness<sup>b</sup>: awakens</p><p>only to tactile stimulus,</p><p>or</p><p><strong>&nbsp;</strong></p><p>seizures<sup>b</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any clinical seizure, focal or generalised that resolves rapidly,</p><p>or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, or</p><p>raised intracranial</p><p>pressure: focal/local</p><p>oedema<sup>b</sup> on</p><p>neuroimaging<sup>c</sup></p></td><td style="vertical-align:top"><p>Treatment with dexamethasone<sup>g</sup></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no response, initiate methylprednisolone 1&nbsp;000&nbsp;mg/day</p><p>Consider non-sedating anti-seizure medicinal products (e.g., levetiracetam) until resolution of ICANS</p><p>&nbsp;</p><p>No concurrent CRS<em>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti‑cytokine therapy not recommended</p><p>&nbsp;</p><p>For ICANS with concurrent CRS<em>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with dexamethasone</p><p>o&nbsp;&nbsp; If no response, initiate methylprednisolone 1&nbsp;000&nbsp;mg/day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choose immunosuppressant alternatives<sup>e</sup> to tocilizumab, if possible</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Permanently discontinue epcoritamab</p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 4<sup>b</sup></strong></p><p>ICE score<sup>c, b</sup> 0</p><p><strong>&nbsp;</strong></p><p>or, depressed level of</p><p>consciousness<sup>b</sup> either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stupor or coma, or</p><p>seizures<sup>b</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening prolonged seizure (&gt;&nbsp;5&nbsp;minutes), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repetitive clinical or electrical seizures without return to baseline in between,</p><p>or</p><p>motor findings<sup>b</sup>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deep focal motor weakness such as hemiparesis or paraparesis, or</p><p>raised intracranial</p><p>pressure / cerebral</p><p>oedema<sup>b</sup>, with</p><p>signs/symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diffuse cerebral oedema on neuroimaging, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decerebrate or decorticate posturing,</p><p>or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cranial nerve VI palsy, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; papilloedema, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cushing&rsquo;s triad</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Treatment with dexamethasone<sup>g</sup>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If no response, initiate methylprednisolone 1&nbsp;000&nbsp;mg/day</p><p>&nbsp;</p><p>Consider non-sedating anti-seizure medicinal products (e.g., levetiracetam) until resolution of ICANS</p><p>&nbsp;</p><p>No concurrent CRS<em>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anti‑cytokine therapy not recommended</p><p>&nbsp;</p><p>For ICANS with concurrent CRS<em>:</em></p><ul><li>Treatment with dexamethasone<ul><li>If no response, initiate methylprednisolone 1&nbsp;000&nbsp;mg/day</li></ul></li><li>Choose immunosuppressant alternatives<sup>e</sup> to tocilizumab, if possible</li></ul></td><td style="vertical-align:top"><p>Permanently discontinue epcoritamab</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>ICANS graded according to ASTCT ICANS Consensus Grading</p><p><sup>b</sup>ICANS grade is determined by the most severe event (ICE score, level of consciousness, seizures, motor findings, raised ICP/cerebral oedema) not attributable to any other cause</p><p><sup>c</sup>If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (name 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., &ldquo;show me 2 fingers&rdquo; or &ldquo;close your eyes and stick out your tongue&rdquo; = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points.</p><p><sup>d</sup>Dexamethasone should be administered at 10&nbsp;mg intravenously every 12&nbsp;hours</p><p><sup>e</sup>Riegler L et al. (2019)</p><p><sup>f</sup>Dexamethasone 10-20&nbsp;mg intravenously every 12&nbsp;hours</p><p><sup>g</sup>Dexamethasone 10-20&nbsp;mg intravenously every 6&nbsp;hours</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><strong>Table </strong><strong>6 Recommended dose modifications for other adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Adverse Reaction<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Severity<sup>1</sup></strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections (see section 4.4)</p></td><td style="vertical-align:top"><p>Grades 1-4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold epcoritamab in patients with active infection, until the infection resolves</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For Grade 4, consider permanent discontinuation of epcoritamab</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia or<em> </em>febrile neutropenia (see section 4.8)</p></td><td style="vertical-align:top"><p>Absolute neutrophil count less than 0.5&nbsp;x&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold epcoritamab until absolute neutrophil count is 0.5&nbsp;x&nbsp;10<sup>9</sup>/L or higher</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia (see section 4.8)</p></td><td style="vertical-align:top"><p>Platelet count</p><p>less than 50&nbsp;x&nbsp;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold epcoritamab until platelet count is 50&nbsp;x&nbsp;10<sup>9</sup>/L or higher</p></td></tr><tr><td style="vertical-align:top"><p>Other adverse reactions (see section 4.8)</p></td><td style="vertical-align:top"><p>Grade 3 or higher</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold epcoritamab until the toxicity resolves to Grade 1 or baseline</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Missed or delayed dose</u></p><p><u>&nbsp;</u></p><p><em>Diffuse large B-cell lymphoma</em></p><p>A re-priming Cycle (identical to Cycle 1 with standard CRS prophylaxis) is required:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 8&nbsp;days between the priming dose (0.16&nbsp;mg) and intermediate dose (0.8&nbsp;mg), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 14&nbsp;days between the intermediate dose (0.8&nbsp;mg) and first full dose (48&nbsp;mg), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 6&nbsp;weeks between full doses (48&nbsp;mg)</p><p>After the re-priming cycle, the patient should resume treatment with Day 1 of the next planned treatment cycle (subsequent to the cycle during which the dose was delayed).</p><p><em>&nbsp;</em></p><p><em>Follicular lymphoma</em></p><p>A re-priming Cycle (identical to Cycle 1 with standard CRS prophylaxis) is required:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 8 days between the priming dose (0.16&nbsp;mg) and intermediate dose (0.8&nbsp;mg), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 8 days between the intermediate dose (0.8&nbsp;mg) and the second intermediate dose (3&nbsp;mg), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 14&nbsp;days between the second intermediate dose (3&nbsp;mg) and first full dose (48&nbsp;mg), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there are more than 6&nbsp;weeks between any two full doses (48&nbsp;mg)</p><p>After the re-priming cycle, the patient should resume treatment with Day 1 of the next planned treatment cycle (subsequent to the cycle during which the dose was delayed).</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>Dose adjustments are not considered necessary in patients with mild to moderate renal impairment. Epcoritamab has not been studied in patients with severe renal impairment to end stage renal disease.</p><p>No dose recommendations can be made for patients with severe renal impairment to end-stage renal disease (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>Dose adjustments are not considered necessary in patients with mild hepatic impairment. Epcoritamab has not been studied in patients with severe hepatic impairment (defined as total bilirubin &gt;&nbsp;3 times ULN and any AST) and data are limited in patients with moderate hepatic impairment (defined as total bilirubin &gt;&nbsp;1.5 to 3 times ULN and any AST). No dose recommendations can be made for patients with moderate to severe hepatic impairment (see section 5.2).</p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>&nbsp;</p><p>No dose adjustment is necessary in patients &ge;&nbsp;65&nbsp;years of age (see sections 5.1 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>The safety and efficacy of Tepkinly in children aged less than 18&nbsp;years of age have not yet been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Tepkinly is for subcutaneous use. It should be administered by subcutaneous injection only, preferably in the lower part of the abdomen or the thigh. Change of injection site from left to right side or vice versa is recommended especially during the weekly administration schedule (i.e., Cycles 1-3)<em>.</em></p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p><u>&nbsp;</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Cytokine release syndrome (CRS)</u></p><p><u>&nbsp;</u></p><p>CRS, which may be life-threatening or fatal, occurred in patients receiving epcoritamab. The most common signs and symptoms of CRS include pyrexia, hypotension and hypoxia. Other signs and symptoms of CRS in more than two patients include chills, tachycardia, headache and dyspnoea.</p><p>&nbsp;</p><p>Most CRS events occurred in Cycle 1 and were associated with the first full dose of epcoritamab. Administer prophylactic corticosteroids to mitigate the risk of CRS (see section 4.2).</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of CRS following epcoritamab administration.</p><p>&nbsp;</p><p>At the first signs or symptoms of CRS, treatment should be instituted of supportive care with tocilizumab and/or corticosteroids as appropriate (see section 4.2, Table 4). Patients should be counselled on the signs and symptoms associated with CRS and patients should be instructed to contact their healthcare professional and seek immediate medical attention should signs or symptoms occur at any time. Management of CRS may require either temporary delay or discontinuation of epcoritamab based on the severity of CRS (see section 4.2).</p><p>&nbsp;</p><p>Patients with DLBCL should be hospitalised for 24&nbsp;hours after administration of the Cycle 1 Day 15 dose of 48&nbsp;mg to monitor for signs and symptoms of CRS.</p><p>&nbsp;</p><p><u>Immune effector cell-associated neurotoxicity syndrome (ICANS)</u></p><p><u>&nbsp;</u></p><p>ICANS, including a fatal event, have occurred in patients receiving epcoritamab. ICANS may manifest as aphasia, altered level of consciousness, impairment of cognitive skills, motor weakness, seizures, and cerebral oedema.</p><p>&nbsp;</p><p>The majority of cases of ICANS occurred within Cycle 1 of epcoritamab treatment, however some occurred with delayed onset.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of ICANS following epcoritamab administration.</p><p>At the first signs or symptoms of ICANS, treatment with corticosteroids and non-sedating-anti-seizure medicinal products should be instituted as appropriate (see section 4.2, Table 5). Patients should be counselled on the signs and symptoms of ICANS and that the onset of events may be delayed. Patients should be instructed to contact their healthcare professional and seek immediate medical attention should signs or symptoms occur at any time. Epcoritamab should be delayed or discontinued as recommended (see section 4.2).</p><p>&nbsp;</p><p>Patients with DLBCL should be hospitalised for 24&nbsp;hours after administration of the Cycle 1 Day 15 dose of 48&nbsp;mg to monitor for signs and symptoms of ICANS.</p><p><u>&nbsp;</u></p><p><u>Serious infections</u></p><p>&nbsp;</p><p>Treatment with epcoritamab may lead to an increased risk of infections. Serious or fatal infections were observed in patients treated with epcoritamab in clinical studies (see section 4.8).</p><p>&nbsp;</p><p>Administration of epcoritamab should be avoided in patients with clinically significant active systemic infections.</p><p>As appropriate, prophylactic antimicrobials should be administered prior to and during treatment with epcoritamab (see section 4.2). Patients should be monitored for signs and symptoms of infection, before and after epcoritamab administration, and treated appropriately. In the event of febrile neutropenia, patients should be evaluated for infection and managed with antibiotics, fluids and other supportive care, according to local guidelines.</p><p>&nbsp;</p><p><u>Tumour lysis syndrome (TLS)</u></p><p>&nbsp;</p><p>TLS has been reported in patients receiving epcoritamab (see section 4.8). Patients at an increased risk for TLS are recommended to receive hydration and prophylactic treatment with a uric acid lowering agent. Patients should be monitored for signs or symptoms of TLS, especially patients with high tumour burden or rapidly proliferative tumours, and patients with reduced renal function. Patients should be monitored for blood chemistries and abnormalities should be managed promptly.</p><p><u>&nbsp;</u></p><p><u>Tumour flare</u></p><p><u>&nbsp;</u></p><p>Tumour flare has been reported in patients treated with epcoritamab (see section 4.8). Manifestations could include localised pain and swelling. Consistent with the mechanism of action of epcoritamab, tumour flare is likely due to the influx of T-cells into tumour sites following epcoritamab administration.</p><p>&nbsp;</p><p>There are no specific risk factors for tumour flare that have been identified; however, there is a heightened risk of compromise and morbidity due to mass effect secondary to tumour flare in patients with bulky tumours located in close proximity to airways and/or a vital organ. Patients treated with epcoritamab should be monitored and evaluated for tumour flare at critical anatomical sites.</p><p>&nbsp;</p><p><u>CD20-negative disease </u></p><p><u>&nbsp;</u></p><p>There are limited data available on patients with CD20-negative DLBCL and patients with CD20-negative FL treated with &nbsp;epcoritamab and it is possible that patients with CD20-negative DLBCL and patients with CD20-negative FL may have less benefit compared to patients with CD20-positive DLBCL and patients with CD20-positive FL, respectively. The potential risks and benefits associated with treatment of patients with CD20-negative DLBCL and FL with epcoritamab should be considered.</p><p>&nbsp;</p><p><u>Patient card</u></p><p>&nbsp;</p><p>The doctor must inform the patient of the risk of CRS and ICANS and any signs and symptoms of CRS and ICANS. Patients must be instructed to seek immediate medical attention if they experience signs and symptoms of CRS and/or ICANS. Patients should be provided with a patient card and instructed to carry the card at all times. This card describes symptoms of CRS and ICANS which, if experienced, should prompt the patient to seek immediate medical attention.</p><p>&nbsp;</p><p><u>Immunisation</u></p><p>&nbsp;</p><p>Live and/or live-attenuated vaccines should not be given during epcoritamab therapy. Studies have not been conducted in patients who received live vaccines.</p><p><em>&nbsp;</em></p><p><u>Excipients with known effect</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p><p>This medicinal product contains 21.9&nbsp;mg of sorbitol per vial, which is equivalent to 27.33&nbsp;mg/ml.</p><p>&nbsp;</p><p>This medicinal product contains 0.42&nbsp;mg of polysorbate 80 per vial, equivalent to 0.4&nbsp;mg/ml. Polysorbate 80 may cause allergic reactions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p><p>Transient elevation of certain proinflammatory cytokines by epcoritamab may suppress CYP450 enzyme activities. On initiation of epcoritamab therapy in patients being treated with CYP450 substrates with a narrow therapeutic index, therapeutic monitoring should be considered.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in females</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should be advised to use effective contraception during treatment with epcoritamab and for at least 4&nbsp;months after the last dose. Verify pregnancy status in females of reproductive potential prior to initiating epcoritamab treatment.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Based on its mechanism of action, epcoritamab may cause foetal harm, including B-cell lymphocytopenia and alterations in normal immune responses, when administered to pregnant women. There are no data on the use of epcoritamab in pregnant women. Animal reproduction studies have not been conducted with epcoritamab. IgG1 antibodies, such as epcoritamab, can cross the placenta resulting in foetal exposure. Advise pregnant women of the potential risk to a foetus.</p><p>Epcoritamab is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether epcoritamab is excreted in human milk or its effect on milk production. Since IgGs are known to be present in milk, neonatal exposure to epcoritamab may occur via lactational transfer. Breast‑feeding should be discontinued during treatment with epcoritamab and for at least 4&nbsp;months after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No fertility studies have been conducted with epcoritamab (see section 5.3). The effect of epcoritamab on male and female fertility is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epcoritamab has minor influence on the ability to drive and use machines. Due to the potential for ICANS, patients should be advised to exercise caution while (or avoid if symptomatic) driving, cycling or using heavy or potentially dangerous machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><em>&nbsp;</em></p><p>The safety of epcoritamab was evaluated in a non-randomised, single-arm GCT3013-01 study in 382 patients with relapsed or refractory large B-cell lymphoma (N=167), follicular lymphoma (N=129) and follicular lymphoma (3-step step-up dose schedule N=86) after two or more lines of systemic therapy and included all the patients who enrolled to the 48&nbsp;mg dose and received at least one dose of epcoritamab.</p><p>&nbsp;</p><p>The median duration of exposure to epcoritamab was 4.9&nbsp;months (range: &lt;1 to 30&nbsp;months).</p><p>&nbsp;</p><p>The most common adverse reactions (&ge;&nbsp;20%) were CRS, injection site reactions, fatigue, viral infection, neutropenia, musculoskeletal pain, pyrexia, and diarrhoea.</p><p>&nbsp;</p><p>Serious adverse reactions occurred in 50% of patients. The most frequent serious adverse reaction (&ge;&nbsp;10%) was cytokine release syndrome (34%). Fourteen patients (3.7%) experienced a fatal adverse reaction (pneumonia in 9 (2.4%) patients, viral infection in 4 (1.0%) patients, and ICANS in 1 (0.3%) patient).</p><p>&nbsp;</p><p>Adverse reactions that led to discontinuation occurred in 6.8% of patients. Discontinuation of epcoritamab due to pneumonia occurred in 14 (3.7%) patients, viral infection in 8 (2.1%) patients, fatigue in 2 (0.5%) patients, and CRS, ICANS, , or diarrhoea, in 1 (0.3%) patient each.</p><p>&nbsp;</p><p>Dose delays due to adverse reactions occurred in 42% of patients. Adverse reactions leading to dose delays (&ge;&nbsp;3%) were viral infections (17%), CRS (11%), neutropenia (5.2%), pneumonia (4.7%), upper respiratory tract infection (4.2%), and pyrexia (3.7%).</p><p><em>&nbsp;</em></p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions for epcoritamab from clinical studies (Table 7) are listed by MedDRA system organ class and are based on the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); and very rare (&lt;&nbsp;1/10&nbsp;000).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 7 Adverse reactions reported in patients with relapsed or refractory LBCL or FL treated with epcoritamab in GCT3013-01 study</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:629px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class / preferred term or adverse reaction</strong></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><strong>All grades</strong></p><p><em>&nbsp;</em></p></td><td style="vertical-align:top"><p><strong>Grade 3-4</strong></p><p>&nbsp;</p><p><em>&nbsp;</em></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Infections and infestations </strong></p></td></tr><tr><td style="vertical-align:top"><p>Viral infection<sup>a</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia<sup>b</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>c</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infection<sup>d</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis<sup>e</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Cellulitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Neoplasm benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tumour flare</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>f</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>g</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>h</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia<sup>i</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cytokine release syndrome<sup>j</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Tumour lysis syndrome<sup>k</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Immune effector cell-associated neurotoxicity syndrome<sup>j</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmias<sup>l</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pleural effusion</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>m</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>n</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal pain<sup>o</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Injection site reactions<sup>p</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>q</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia<sup>r</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Oedema<sup>s</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood sodium decreased<sup>t</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Adverse reactions were graded using NCI CTCAE version 5.0</p><p><sup>a</sup>Viral infection includes COVID-19, cytomegalovirus chorioretinitis, cytomegalovirus colitis, cytomegalovirus infection, cytomegalovirus infection reactivation, gastroenteritis viral, herpes simplex, herpes simplex reactivation, herpes virus infection, herpes zoster, oral herpes, post-acute&nbsp;COVID-19&nbsp;syndrome,&nbsp;and varicella&nbsp;zoster&nbsp;virus&nbsp;infection</p><p><sup>b</sup>Pneumonia includes COVID-19 pneumonia and pneumonia</p><p><sup>c</sup>Upper respiratory tract infection includes laryngitis, pharyngitis, respiratory syncytial virus infection, rhinitis, rhinovirus infection, and upper respiratory tract infection</p><p><sup>d</sup>Fungal infection includes candida infection, oesophageal candidiasis, oral candidiasis and oropharyngeal&nbsp;candidiasis</p><p><sup>e</sup>Sepsis includes bacteraemia, sepsis, and septic shock</p><p><sup>f</sup>Neutropenia includes neutropenia and neutrophil count decreased</p><p><sup>g</sup>Anaemia includes anaemia and serum ferritin decreased</p><p><sup>h</sup>Thrombocytopenia includes platelet count decreased and thrombocytopenia</p><p><sup>i</sup>Lymphopenia includes lymphocyte count decreased and lymphopenia</p><p><sup>j </sup>Events&nbsp;graded using American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria</p><p><sup>k </sup>Clinical&nbsp;Tumour Lysis Syndrome was graded based on Cairo-Bishop</p><p><sup>l</sup>Cardiac arrhythmias include bradycardia, sinus bradycardia, sinus tachycardia, supraventricular tachycardia, and tachycardia</p><p><sup>m</sup>Abdominal pain includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal tenderness</p><p><sup>n</sup>Rash includes rash, rash erythematous, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular, and rash vesicular</p><p><sup>o</sup>Musculoskeletal pain includes back pain, bone pain, flank pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, pain, pain in extremity, and spinal pain</p><p><sup>p</sup>Injection site reactions include injection site bruising, injection site erythema, injection site hypertrophy, injection site inflammation, injection site mass, injection site nodule, injection site oedema, injection site pain, injection site pruritus, injection site rash, injection site reaction, injection site swelling, and injection site urticaria.</p><p><sup>q</sup>Fatigue includes asthenia, fatigue, and lethargy</p><p><sup>r</sup>Pyrexia includes body temperature increased and pyrexia</p><p><sup>s</sup>Oedema includes face oedema, generalised oedema, oedema, oedema peripheral, peripheral swelling, swelling,&nbsp;and swelling&nbsp;face</p><p><sup>t</sup>Blood sodium decreased includes blood sodium decreased and hyponatraemia</p><p><em>&nbsp;</em></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Cytokine release syndrome</em></p><p><em>&nbsp;</em></p><p><em><u>2-step step-up dose</u></em><em><u> schedule (large B-cell lymphoma and follicular lymphoma)</u></em></p><p>In study GCT3013-01, CRS of any grade occurred in 58% (171/296) of patients with large B-cell lymphoma and follicular lymphoma treated with epcoritamab at the 2-step step-up dose schedule. The incidence of Grade 1 was 35%, Grade 2 was 21%, and Grade 3 occurred in 2.4% of patients. Recurrent CRS occurred in 21% of patients. CRS of any grade occurred in 9.8% of patients after the priming dose (Cycle 1 Day 1); 13% after the intermediate dose (Cycle 1, Day 8); 51% after the first full dose (Cycle 1, Day 15), 6.5% after the second full dose (Cycle 1 Day 22) and 3.7% after the third full dose (Cycle 2 Day 1) or beyond. The median time to onset of CRS from the most recent administered epcoritamab dose was 2&nbsp;days (range: 1 to 12&nbsp;days). The median time to onset after the first full dose was 19.3&nbsp;hours (range: &lt;0.1 to 7&nbsp;days). CRS resolved in 99% of patients, and the median duration of CRS events was 2&nbsp;days (range 1 to 54&nbsp;days).</p><p>&nbsp;</p><p>Of the 171 patients that experienced CRS, the most common signs and symptoms of CRS included pyrexia 99%, hypotension 32% and hypoxia 16%. Other signs and symptoms of CRS in &ge;3% of patients included chills (11%), tachycardia (including sinus tachycardia (11%)), &nbsp;headache (8.2%), nausea (4.7%), and vomiting (4.1%). Transient elevated liver enzymes (ALT or AST &gt;&nbsp;3xULN) were concurrent with CRS in 4.1% of patients with CRS. See section 4.2 and 4.4 for monitoring and management guidance.</p><p><em><u>&nbsp;</u></em></p><p><em><u>3-step step-up dose schedule follicular lymphoma</u></em><em><u> </u></em></p><p>In study GCT3013-01, CRS of any grade occurred in 49% (42/86) of patients treated with epcoritamab at the recommended follicular lymphoma 3-step step-up dose schedule. The incidence of Grade 1 was 40%, Grade 2 was 9%. There were no Grade &ge;3 CRS events reported. Recurrent CRS occurred in 23% of patients. Most CRS events occurred during Cycle 1, where 48% of patients experienced an event. In Cycle&nbsp;1, CRS occurred in 12% of patients after the priming dose (Cycle 1 Day 1), 5.9% of patients after the intermediate dose (Cycle&nbsp;1 Day&nbsp;8), 15% of patients after the second intermediate dose (Cycle&nbsp;1 Day&nbsp;15), and 37% of patients after the first full dose (Cycle&nbsp;1 Day&nbsp;22). The median time to onset of CRS from the most recent administered epcoritamab dose was 59 hours (range: 1 to 8&nbsp;days). The median time to onset after the first full dose was 61 hours (range: 1 to 8 days). CRS resolved in 100% of patients and the median duration of CRS events was 2 days (range 1 to 14&nbsp;days).</p><p>&nbsp;</p><p>Serious adverse reactions due to CRS occurred in 28% of patients who received epcoritamab.</p><p>Dose delays due to CRS occurred in 19% of patients who received epcoritamab.</p><p>&nbsp;</p><p>Of the 42 patients that experienced CRS at the recommended dose, the most common (&ge;10%) signs and symptoms of CRS included pyrexia (100%) and hypotension (14%). In addition to corticosteroid use, tocilizumab was used to manage CRS event in 12% of patients.</p><p>&nbsp;</p><p><em>Immune effector cell-associated neurotoxicity syndrome</em><u> </u></p><p><em>&nbsp;</em></p><p>In study GCT3013-01, ICANS occurred in 4.7% (18/382) of patients treated with epcoritamab; 3.1% experienced Grade 1 and 1.3% experienced Grade 2. One patient (0.3%) experienced an ICANS event of Grade 5 (fatal). The median time to first ICANS onset from the start of epcoritamab treatment (Cycle 1 Day 1) was 18&nbsp;days (range: 8 to 141&nbsp;days). ICANS resolved in 94% (17/18) of patients with supportive care. The median time to resolution of ICANS was 2&nbsp;days (range: 1 to 9&nbsp;days). In the 18 patients with ICANS, the onset of ICANS was prior to CRS in 11% of patients, concurrent with CRS in 44%, following onset of CRS in 17%, and in the absence of CRS in 28%.</p><p>&nbsp;</p><p><em>Serious infections</em></p><p><em>&nbsp;</em></p><p><em><u>Large B-cell lymphoma</u></em></p><p>In study GCT3013-01, serious infections of any grade occurred in 25% (41/167) of patients with large B-cell lymphoma treated with epcoritamab. The most frequent serious infections included COVID-19 (6.6%), COVID-19 pneumonia (4.2%), pneumonia (3.6%), sepsis (2.4%), upper respiratory tract infection (1.8%), bacteraemia (1.2%), and septic shock (1.2%). The median time to onset of first serious infection from the start of epcoritamab treatment (Cycle 1 Day 1) was 56&nbsp;days (range: 4 to 631&nbsp;days), with median duration of 15&nbsp;days (range: 4 to 125&nbsp;days). Grade 5 events of infections occurred in 7 (4.2%) patients.</p><p>&nbsp;</p><p><em><u>Follicular lymphoma</u></em><em><u> </u></em></p><p>In study GCT3013-01, serious infections of any grade occurred in 32% (68/215) of patients with follicular lymphoma treated with epcoritamab. The most frequent serious infections included COVID-19 (8.8%), COVID-19 pneumonia (5.6%), pneumonia (3.7%), urinary tract infection (1.9%), and pneumocystis jirovecii pneumonia (1.4%). The median time to onset of first serious infection from the start of epcoritamab treatment (Cycle 1 Day 1) was 81 days (range: 1 to 636 days), with median duration of 18&nbsp;days (range: 4 to 249&nbsp;days). Grade 5 events of infection occurred in 8 (3.7%) patients, 6 (2.8%) of which were attributed to COVID-19 or COVID-19 pneumonia.</p><p>&nbsp;</p><p><em>Neutropenia</em></p><p><em>&nbsp;</em></p><p>In study GCT3013-01, neutropenia of any grade occurred in 28% (105/382) of patients, including 23% Grade 3-4 events. The median time to onset of first neutropenia/neutrophil count decreased event was 65&nbsp;days (range: 2 to 750&nbsp;days), with median duration of 15&nbsp;days (range: 2 to 415&nbsp;days). Of the 105 patients who had neutropenia/neutrophil count decreased events, 61% received G-CSF to treat the events.</p><p>&nbsp;</p><p><em>Tumour lysis syndrome </em></p><p><em>&nbsp;</em></p><p>In study GCT3013-01, TLS occurred in 1.0% (4/382) of patients. Median time to onset was 18 days (range 8 to 33 days), and median duration was 3 days (range 2 to 4 days).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Tumour flare </em></p><p><em>&nbsp;</em></p><p>In study GCT3013-01, tumour flare occurred in 1.6% (6/382) of patients, all of which were grade 2. The median time to onset was 19.5&nbsp;days (range 9 to 34&nbsp;days), and median duration was 9&nbsp;days (range 1 to 50&nbsp;days).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>To reports any side effect(s): </u></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdose, monitor the patient for any signs or symptoms of adverse reactions and administer appropriate supportive treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01FX27</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Epcoritamab is a humanised IgG1-bispecific antibody that binds to a specific extracellular epitope of CD20 on B cells and to CD3 on T cells. The activity of epcoritamab is dependent upon simultaneous engagement of CD20-expressing cancer cells and CD3-expressing endogenous T cells by epcoritamab that induces specific T‑cell activation and T‑cell-mediated killing of CD20-expressing cells.</p><p>Epcoritamab Fc region is silenced to prevent target-independent immune effector mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cellular cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Epcoritamab induced rapid and sustained depletion of circulating B‑cells (defined as CD19 B-cell counts &nbsp;&le;10 cell/&micro;l) in the subjects who have detectable B cells at treatment initiation. There were 21% subjects (n=33) with DLBCL and 50% subjects (n=56) with FL who had detectable circulating B-cells at treatment initiation. Transient reduction in circulating T cells was observed immediately after each dose in Cycle 1 and followed by T cell expansion in subsequent cycles.</p><p>&nbsp;</p><p>In study GCT3013-01, following subcutaneous administration of epcoritamab at the recommended 2‑step step-up dose schedule in patients with LBCL, transient and modest elevations of circulating levels of selected cytokines (IFN-&gamma;, TNF&alpha;, IL-6, IL-2, and IL-10) occurred mostly after the first full dose (48&nbsp;mg), with peak levels between 1 to 4&nbsp;days post dose. Cytokine levels returned to baseline prior to the next full dose, however elevations of cytokines could also be observed after Cycle 1.</p><p>In study GCT3013-01, following subcutaneous administration of epcoritamab at the recommended 3-step step-up dose schedule in patients with FL, median IL-6 levels associated with CRS risk remained consistently low after each dose in Cycle 1 and beyond, particularly after the first full dose, compared to patients who received the 2-step step-up dose.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>Anti-drug antibodies (ADA) were commonly detected. The incidence of treatment-emergent ADAs with the 2-step step-up dose schedule (0.16/0.8/48&nbsp;mg) in the combined population of DLBCL and FL was 3.4% (3.4 % positive, 93.9% negative and 2.7% indeterminate, N=261 evaluable patients) and 3.3% (3.3% positive, 95% negative and 1.7% indeterminate, N= 60 evaluable patients), in studies GCT3013‑01 and GCT3013-04, respectively.</p><p>The incidence of treatment-emergent ADAs with the 3-step step-up dose schedule (0.16/0.8/3/48&nbsp;mg) in the FL optimisation cohort was 7% (7% positive, 91.5% negative and 1.4% indeterminate, N=71 evaluable patients) in study GCT3013-01. A subject is classified as indeterminate if the patient is confirmed ADA positive at baseline but there is no confirmed positive on-treatment record or if confirmed ADA positive on treatment record titre are equal or lower than baseline.</p><p>&nbsp;</p><p>No evidence of ADA impact on pharmacokinetics, efficacy or safety was observed, however, data are still limited. Neutralising antibodies were not evaluated.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em><u>Diffuse large B-cell lymphoma </u></em></p><p>Study GCT3013-01 was an open-label, multi-cohort, multicentre, single-arm study that evaluated epcoritamab as monotherapy in patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL). The study includes a dose escalation part and an expansion part. The expansion part of the study included an aggressive non-Hodgkin lymphoma (aNHL) cohort, an indolent NHL (iNHL) cohort and a mantle-cell lymphoma (MCL) cohort. The pivotal aNHL cohort consisted of patients with LBCL (N=157), including patients with DLBCL (N=139, 12 patients of which had MYC, BCL2, and/or BCL6 rearrangements i.e., DH/TH), with high-grade B-cell lymphoma (HGBCL) (N=9), with follicular lymphoma grade 3B (FL) (N=5) and patients with primary mediastinal B-cell lymphoma (PMBCL) (N=4). In the DLBCL cohort, 29% (40/139) of patients had transformed DLBCL arising from indolent lymphoma.<em> </em>Patients included in the study were required to have documented CD20+ mature B-cell neoplasm according to WHO classification 2016 or WHO classification 2008 based on representative pathology report, failed prior autologous hematopoietic stem cell transplantation (HSCT) or were ineligible for autologous HSCT, patients who had lymphocyte counts &lt;&nbsp;5&times;10<sup>9</sup>/L, and patients with at least 1 prior anti-CD20 monoclonal antibody-containing therapy.</p><p>The study excluded patients with central nervous system (CNS) involvement of lymphoma, prior treatment with allogeneic HSCT or solid organ transplant, chronic ongoing infectious diseases, any patients with known impaired T‑cell immunity, a creatinine clearance of less than 45<em>&nbsp;</em>ml/min, alanine aminotransferase &gt;&nbsp;3 times the upper limit of normal, cardiac ejection fraction less than 45%, and known clinically significant cardiovascular disease. Efficacy was evaluated in 139&nbsp;patients with DLBCL who had received at least one dose of epcoritamab SC in cycles of 4&nbsp;weeks, i.e., 28&nbsp;days. Epcoritamab monotherapy was administered at the recommended 2-step step-up dose schedule as follows:</p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycle 1: epcoritamab 0.16&nbsp;mg on Day 1, 0.8&nbsp;mg on Day 8, 48&nbsp;mg on Day 15 and Day 22</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycles 2-3: epcoritamab 48&nbsp;mg on Days 1, 8, 15, and 22</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycles 4-9: epcoritamab 48&nbsp;mg on Days 1 and 15</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycles 10 and beyond: epcoritamab 48&nbsp;mg on Day 1</p><p>&nbsp;</p><p>Patients continued to receive epcoritamab until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>The demographics and baseline characteristics are shown in Table &nbsp;8.</p><p>&nbsp;</p><p><strong>Table 8 Demographics and baseline characteristics of patients with DLBCL in GCT3013-01 study</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:532px"><tbody><tr><td style="vertical-align:top"><p><strong>Characteristics </strong></p></td><td style="vertical-align:top"><p><strong>(N=139)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Age</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median, years (min, max)</p></td><td style="vertical-align:top"><p>66 (22, 83)</p></td></tr><tr><td style="vertical-align:top"><p>&lt;&nbsp;65&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>66 (47)</p></td></tr><tr><td style="vertical-align:top"><p>65 to &lt;&nbsp;75&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>44 (32)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;&nbsp;75&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>29 (21)</p></td></tr><tr><td style="vertical-align:top"><p>Males, n (%)</p></td><td style="vertical-align:top"><p>85 (61)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Race, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; White</p></td><td style="vertical-align:top"><p>84 (60)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Asian</p></td><td style="vertical-align:top"><p>27 (19)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Other</p></td><td style="vertical-align:top"><p>5 (4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Not Reported</p></td><td style="vertical-align:top"><p>23 (17)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ECOG performance status; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>67 (48)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 1</p></td><td style="vertical-align:top"><p>67 (48)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>5 (4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Disease stage<sup>c</sup> at initial diagnosis, n (%)</p></td></tr><tr><td style="vertical-align:top"><p>III</p></td><td style="vertical-align:top"><p>16 (12)</p></td></tr><tr><td style="vertical-align:top"><p>IV</p></td><td style="vertical-align:top"><p>86 (62)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Number of prior lines of anti‑lymphoma therapy</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median (min, max)</p></td><td style="vertical-align:top"><p>3 (2, 11)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2, n (%)</p></td><td style="vertical-align:top"><p>41 (30)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3, n (%)</p></td><td style="vertical-align:top"><p>47 (34)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; &ge;&nbsp;4, n (%)</p></td><td style="vertical-align:top"><p>51 (37)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>DLBCL Disease history; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; De Novo DLBCL</p></td><td style="vertical-align:top"><p>97 (70)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; DLBCL transformed from indolent lymphoma</p></td><td style="vertical-align:top"><p>40 (29)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>FISH Analysis Per Central lab<sup>d</sup>, N=88</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong>Double-hit/Triple-hit lymphoma, n (%)&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>12 (14)</p></td></tr><tr><td style="vertical-align:top"><p>Prior autologous HSCT</p></td><td style="vertical-align:top"><p>26 (19)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Prior therapy; n (%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Prior CAR-T</p></td><td style="vertical-align:top"><p>53 (38)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Primary refractory disease<sup>a</sup></p></td><td style="vertical-align:top"><p>82 (59)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Refractory to &ge;&nbsp;2 consecutive lines of prior anti‑lymphoma therapy<sup>b</sup></p></td><td style="vertical-align:top"><p>104 (75)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Refractory to the last line of systemic antineoplastic therapy<sup>b</sup></p></td><td style="vertical-align:top"><p>114 (82)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Refractory to prior anti-CD20 therapy</p></td><td style="vertical-align:top"><p>117 (84)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Refractory to CAR-T</p></td><td style="vertical-align:top"><p>39 (28)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup>A patient is considered to be primary refractory if the patient is refractory to frontline anti‑lymphoma therapy.</p><p><sup>b</sup>A patient is considered to be refractory if the patient either experiences disease progression during therapy or disease progression within <em>&lt;&nbsp;</em>6&nbsp;months after therapy completion. A patient is considered relapsed if the patient had recurred disease &ge;&nbsp;6&nbsp;months after therapy completion.</p><p><sup>c</sup>Per Ann Arbor Staging.</p><p><sup>d</sup>Post hoc central lab FISH analysis was performed on available diagnostic</p><p>baseline tumour tissue sections from 88 DLBCL patients.</p></td></tr></tbody></table><p>&nbsp;</p><p>The primary efficacy endpoint was overall response rate (ORR) determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC). The median follow-up time was&nbsp;15.7 months (range: 0.3 to 23.5 months). The median duration of exposure was 4.1&nbsp;months (range: 0 to &nbsp;23&nbsp;months).</p><p>&nbsp;</p><p><strong>Table 9 Efficacy results in study GCT3013-01 in patients with DLBCL<sup>a</sup></strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:454px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p><p><strong>IRC assessment </strong></p></td><td style="vertical-align:top"><p><strong>Epcoritamab</strong></p><p><strong>(N=139)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR<sup>b</sup>, n (%)</p></td><td style="vertical-align:top"><p>86 (62)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>(53.3, 70)</p></td></tr><tr><td style="vertical-align:top"><p>CR<sup>b</sup>, n (%)</p></td><td style="vertical-align:top"><p>54 (39)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>(30.7, 47.5)</p></td></tr><tr><td style="vertical-align:top"><p>PR, n (%)</p></td><td style="vertical-align:top"><p>32 (23)</p></td></tr><tr><td style="vertical-align:top"><p>(95% CI)</p></td><td style="vertical-align:top"><p>(16.3, 30.9)</p></td></tr><tr><td style="vertical-align:top"><p>DOR<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Median (95% CI), months</p></td><td style="vertical-align:top"><p>15.5 (9.7, NR)</p></td></tr><tr><td style="vertical-align:top"><p>DOCR<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR (12.0, NR)</p></td></tr><tr><td style="vertical-align:top"><p>TTR, median (range), months</p></td><td style="vertical-align:top"><p>1.4 (1, 8.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI = confidence interval; CR = complete response; DOR = duration of response; DOCR = duration of complete response; IRC = independent review committee; ORR = overall response rate; PR = partial response; TTR = time to response</p><p><sup>a</sup>Determined by Lugano criteria (2014) as assessed by independent review committee (IRC)</p><p><sup>b</sup>Included patients with initial PD by Lugano or IR by LYRIC who later obtained PR/CR.</p></td></tr></tbody></table><p>&nbsp;</p><p>The median time to CR was 2.6&nbsp;months (range: 1.2 to 10.2&nbsp;months).</p><p>&nbsp;</p><p><em><u>Follicular lymphoma </u></em></p><p>&nbsp;</p><p>Study GCT3013-01 was an open-label, multi-cohort, multicentre, single-arm trial that evaluated epcoritamab as monotherapy in patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The study includes a dose escalation part, an expansion part and a 3‑step step-up dose optimisation part. The expansion part of the study included an aggressive non‑Hodgkin lymphoma (aNHL) cohort, an indolent NHL (iNHL) cohort and a mantle-cell lymphoma (MCL) cohort. The pivotal iNHL cohort, included patients with FL. Patients included in the study were required to have documented CD20+ mature B-cell neoplasm according to WHO classification 2016 or WHO classification 2008 based on representative pathology report with histologic confirmed FL 1-3A at initial diagnosis without clinical or pathological evidence of transformation. All patients had relapsed or refractory disease to the last prior line therapy and previously treated with at least 2 lines of systemic antineoplastic therapy, including at least 1 anti-CD20 monoclonal antibody-containing therapy and an alkylating agent or lenalidomide. The study excluded patients with CNS involvement of lymphoma<strong>, </strong>allogeneic HSCT or solid organ transplant, ongoing active infectious diseases, any patients with known impaired T-cell immunity, a creatinine clearance of less than 45&nbsp;ml/min, alanine aminotransferase &gt;3&nbsp;times the upper limit of normal and cardiac ejection fraction less than 45%. Efficacy was evaluated in 128 patients who had received epcoritamab subcutaneously (SC) in cycles of 4 weeks, i.e., 28 days. Epcoritamab was administered as a monotherapy in a 2-step step-up dose schedule as follows:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycle 1: epcoritamab 0.16&nbsp;mg on Day 1, 0.8&nbsp;mg on Day 8, 48&nbsp;mg on Day 15 and 48&nbsp;mg on Day&nbsp;22</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycles 2-3: epcoritamab 48&nbsp;mg on Days 1, 8, 15, and 22</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycles 4-9: epcoritamab 48&nbsp;mg on Days 1 and 15</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycles 10 and beyond: epcoritamab 48&nbsp;mg on Day 1</p><p>&nbsp;</p><p>Patients continued to receive epcoritamab until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>The median number of cycles initiated was 8 and 60% received at least 6 cycles.</p><p>&nbsp;</p><p>The demographics and baseline characteristics are shown in Table 10.</p><p>&nbsp;</p><p><strong>Table 10 Demographics and baseline characteristics of patients with FL in GCT3013-01 study</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:538px"><thead><tr><td style="vertical-align:top"><p><strong>Characteristics </strong></p></td><td style="vertical-align:top"><p><strong><u>(N = 128)</u></strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median, years (min, max)</p></td><td style="vertical-align:top"><p>65 (39, 84)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; &lt;&nbsp;65&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>61 (48)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; 65 to &lt;&nbsp;75&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>50 (39)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; &ge;&nbsp;75&nbsp;years, n (%)</p></td><td style="vertical-align:top"><p>17 (13)</p></td></tr><tr><td style="vertical-align:top"><p>Males, (%)</p></td><td style="vertical-align:top"><p>79 (62)</p></td></tr><tr><td style="vertical-align:top"><p>Race, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; White</p></td><td style="vertical-align:top"><p>77 (60)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Asian</p></td><td style="vertical-align:top"><p>7 (6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Other</p></td><td style="vertical-align:top"><p>2 (1.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Not Reported</p></td><td style="vertical-align:top"><p>42 (33)</p></td></tr><tr><td style="vertical-align:top"><p>ECOG performance status; n (%)</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>70 (55)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 1</p></td><td style="vertical-align:top"><p>51 (40)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>7 (6)</p></td></tr><tr><td style="vertical-align:top"><p>Number of prior lines of therapies, n (%)</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Median (min, max)</p></td><td style="vertical-align:top"><p>3 (2, 9)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>47 (37)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 3</p></td><td style="vertical-align:top"><p>41 (32)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; &ge;4</p></td><td style="vertical-align:top"><p>40 (31)</p></td></tr><tr><td style="vertical-align:top"><p>Ann Arbor Staging; (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Stage III/IV</p></td><td style="vertical-align:top"><p>109 (85)</p></td></tr><tr><td style="vertical-align:top"><p>FLIPI at baseline, n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>31 (24)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 3- 5</p></td><td style="vertical-align:top"><p>78 (61)</p></td></tr><tr><td style="vertical-align:top"><p>Bulky Disease, n (%)</p></td><td style="vertical-align:top"><p>33 (26)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prior Therapy; n (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Autologous stem cell transplant</p></td><td style="vertical-align:top"><p>24 (19)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Chimeric antigen receptor (CAR)-T cell therapy</p></td><td style="vertical-align:top"><p>6 (5)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Rituximab plus lenalidomide therapy&nbsp;</p></td><td style="vertical-align:top"><p>27 (21)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; PI3K inhibitor</p></td><td style="vertical-align:top"><p>29 (23)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Progression of disease within 24 months of first systemic therapy</p></td><td style="vertical-align:top"><p>67 (52)</p></td></tr><tr><td style="vertical-align:top"><p>Refractory to:</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; &nbsp;&ge; 2 consecutive lines of prior anti-lymphoma therapy</p></td><td style="vertical-align:top"><p>70 (55)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; The last line of systemic antineoplastic therapy</p></td><td style="vertical-align:top"><p>88 (69)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Prior anti-CD20 monoclonal antibody therapy</p></td><td style="vertical-align:top"><p>101 (79)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Both anti-CD20 monoclonal antibody and alkylator therapy</p></td><td style="vertical-align:top"><p>90 (70)</p></td></tr></tbody></table><p>&nbsp;</p><p>Efficacy was established based on overall response rate (ORR) determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC). The median follow-up for DOR was 16.2&nbsp;months. Efficacy results are summarised in Table 11.</p><p>&nbsp;</p><p><strong>Table 11 Efficacy Results in Study GCT3013-01 in FL Patients</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:502px"><thead><tr><td style="vertical-align:top"><p><strong>Endpoint</strong><sup> a</sup><strong>&nbsp;&nbsp; </strong></p><p><strong>IRC assessment </strong></p></td><td style="vertical-align:top"><p><strong>Epcoritamab</strong></p><p><strong>(N=128)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ORR<sup> b</sup>, n (%)</p></td><td style="vertical-align:top"><p>106 (83)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; (95% CI)</p></td><td style="vertical-align:top"><p>(75.1, 88.9)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;CR<sup>b</sup>, n (%)</p></td><td style="vertical-align:top"><p>81 (63)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>(54.3, 71.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;PR<sup> b</sup>, n (%)</p></td><td style="vertical-align:top"><p>25 (20)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;(95% CI)</p></td><td style="vertical-align:top"><p>(13.1, 27.5)</p></td></tr><tr><td style="vertical-align:top"><p>DOR<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median (95% CI), months</p></td><td style="vertical-align:top"><p>21.4 (13.7, NR)</p></td></tr><tr><td style="vertical-align:top"><p>DOCR<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Median (95% CI), months</p></td><td style="vertical-align:top"><p>NR (21.4, NR)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 12-month estimate, % (95% CI)</p></td><td style="vertical-align:top"><p>78.6 (67.3, 86.4)</p></td></tr><tr><td style="vertical-align:top"><p>TTR, median (range), months</p></td><td style="vertical-align:top"><p>1.4 (1, 3)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CI = confidence interval; CR = complete response; DOR = duration of response; DOCR = duration of complete response; IRC = independent review committee; ORR = overall response rate; PFS = progression-free survival; TTR = time to response</p><p><sup>a </sup>determined by Lugano criteria (2014) as assessed by independent review committee (IRC)</p><p><sup>b</sup>Included patients with initial PD by Lugano or IR by LYRIC who later obtained PR/CR.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The median time to CR was 1.5 months (range: 1.2 to 11.1 months).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with epcoritamab in one or more subsets of the paediatric population in the treatment of mature B-cell malignancies, as per paediatric investigation plan (PIP) decision, for the granted indication (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The population pharmacokinetics following subcutaneous administration of epcoritamab was described by a two-compartment model with first order subcutaneous absorption and target-mediated drug elimination. The moderate to high pharmacokinetic variability for epcoritamab was observed and characterised by inter-individual variability (IIV) ranging from 25.7% to 137.5% coefficient of variation (CV) for epcoritamab PK parameters.</p><p>&nbsp;</p><p>In patients with LBCL in study GCT3013-01, based on individually estimated exposures using population pharmacokinetic modelling, following the recommended 2-step step-up dose schedule SC dose of epcoritamab 48&nbsp;mg, the geometric mean (% CV) C<sub>max</sub>&nbsp;of epcoritamab is 10.8&nbsp;mcg/ml (41.7%) and AUC<sub>0-7d&nbsp;</sub>is 68.9&nbsp;day*mcg/ml (45.1%) at the end of the weekly dosing schedule. The C<sub>trough</sub> at Week 12 is 8.4&nbsp;(53.3%)&nbsp;mcg/ml.The geometric mean (% CV) C<sub>max</sub>&nbsp;of epcoritamab is 7.52&nbsp;mcg/ml (41.1%) and AUC<sub>0-14d </sub>is 82.6&nbsp;day*mcg/ml (49.3%) at the end of q2w schedule. The C<sub>trough</sub> for q2W schedule is 4.1&nbsp;(73.9%)&nbsp;mcg/ml.The geometric mean (% CV) C<sub>max </sub>of epcoritamab is 4.76&nbsp;mcg/ml (51.6%) and AUC<sub>0-28d </sub>is 74.3&nbsp;day*mcg/ml (69.5%) at steady state during the q4w schedule. The C<sub>trough</sub> for q4W schedule is 1.2&nbsp;(130%)&nbsp;mcg/ml.</p><p>&nbsp;</p><p>Exposure parameters of epcoritamab in patients with FL were consistent with the exposure parameters seen in the patients with LBCL. Epcoritamab exposures are similar between FL subjects who received the 3-step step-up dose schedule and 2-step step-up dose schedule except for transiently lower trough concentrations, as expected, at Cycle 1 Day 15 after the second intermediate dose (3&nbsp;mg) with 3-step step-up dose schedule compared first full 48&nbsp;mg dose with 2-step step-up dose schedule.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>The peak concentrations occurred around 3-4 days (T<sub>max</sub>) in patients with LBCL receiving the 48&nbsp;mg full dose.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The geometric mean (% CV) central volume of distribution is 8.27&nbsp;l (27.5%) and apparent steady-state volume of distribution is 25.6&nbsp;l (81.8%) based on population PK modelling.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>The metabolic pathway of epcoritamab has not been directly studied. Like other protein therapeutics, epcoritamab is expected to be degraded into small peptides and amino acids via catabolic pathways.</p><p><em>&nbsp;</em></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Epcoritamab is expected to undergo saturable target mediated clearance. The geometric mean (% CV) clearance (l/day) is 0.441 (27.8%). The half-life of epcoritamab is concentration dependent. The population PK model-derived geometric mean half-life of full dose epcoritamab (48&nbsp;mg) ranged from 22 to 25&nbsp;days based on frequency of dosing.</p><p><em>&nbsp;</em></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p>No clinically important effects on the pharmacokinetics of epcoritamab (Cycle 1 AUC within approximately 36%) were observed based on age (20 to 89&nbsp;years), sex, or race/ethnicity (white, Asian, and other), mild to moderate renal impairment creatinine clearance (CLcr &ge;&nbsp;30 ml/min to CLcr &lt;&nbsp;90&nbsp;ml/min), and mild hepatic impairment (total bilirubin &le;&nbsp;ULN and AST &gt;&nbsp;ULN, or total bilirubin 1 to 1.5&nbsp;times ULN and any AST) after accounting for differences in bodyweight. No patients with severe to end-stage renal disease (CLcr &lt;&nbsp;30&nbsp;ml/min) or severe hepatic impairment (total bilirubin &gt;&nbsp;3 times ULN and any AST) have been studied. There is very limited data in moderate hepatic impairment (total bilirubin &gt;&nbsp;1.5 to 3 times ULN and any AST, N=1). Therefore, the pharmacokinetics of epcoritamab is unknown in these populations.</p><p>&nbsp;</p><p>Like other therapeutic proteins, body weight (39 to 172&nbsp;kg) has a statistically significant effect on the pharmacokinetics of epcoritamab. Based on exposure-response analysis and clinical data, considering the exposures in patients at either low body weight (e.g., 46&nbsp;kg) or high body weight (e.g., 105&nbsp;kg) and across body weight categories (&lt;&nbsp;65&nbsp;kg, 65-&lt;&nbsp;85, &ge;&nbsp;85), the effect on exposures is not clinically relevant.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The pharmacokinetics of epcoritamab in paediatric patients has not been established.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Animal pharmacology and/or toxicology</u></p><p>&nbsp;</p><p>No reproductive or developmental toxicity studies in animals have been conducted with epcoritamab.</p><p>Effects generally consistent with the pharmacologic mechanism of action of epcoritamab were observed in cynomolgus monkeys. These findings included dose-related adverse clinical signs (including vomiting, decreased activity, and mortality at high doses) and cytokine release, reversible hematologic alterations, reversible B-cell depletion in peripheral blood, and reversible decreased lymphoid cellularity in secondary lymphoid tissues.</p><p>&nbsp;</p><p><u>Mutagenicity</u></p><p><u>&nbsp;</u></p><p>Mutagenicity studies have not been conducted with epcoritamab.</p><p>&nbsp;</p><p><u>Carcinogenicity</u></p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with epcoritamab.</p><p>&nbsp;</p><p><u>Impairment of fertility</u></p><p><u>&nbsp;</u></p><p>Animal fertility studies have not been conducted with epcoritamab, however, epcoritamab did not cause toxicological changes in the reproductive organs of male or female cynomolgus monkeys at doses up to 1&nbsp;mg/kg/week in intravenous general toxicity study of 5-week duration. The AUC exposures (time-averaged over 7&nbsp;days) at the high dose in cynomolgus monkeys were similar to those in patients (AUC0-7d) receiving the recommended dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium acetate trihydrate</p><p>Acetic acid</p><p>Sorbitol (E420)</p><p>Polysorbate 80</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products and/or diluents except those listed in section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

2 years.

Diluted or prepared epcoritamab
Chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C to 8 °C including up to 12 hours at room temperature (20-25 °C).

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C, unless dilution has taken place in controlled and validated aseptic conditions.

Minimise exposure to daylight. Allow epcoritamab solution to equilibrate to room temperature before administration. Discard unused epcoritamab solution beyond the allowable storage time.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&nbsp;&deg;C to 8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution /first opening of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass vial with a bromobutyl rubber stopper coated with fluoropolymer at the contact site and aluminium seal with a plastic light blue flip off cap, containing 4&nbsp;mg per 0.8&nbsp;ml solution for injection.</p><p>&nbsp;</p><p>Each carton contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epcoritamab must be prepared and administered by a healthcare provider as a subcutaneous injection.</p><p>Each vial of epcoritamab is intended for single use only.</p><p>&nbsp;</p><p>Each vial contains an overfill that allows withdrawal of the labelled amount.</p><p>&nbsp;</p><p>The administration of epcoritamab takes place over the course of 28-day cycles, following the dosing schedule in section 4.2.</p><p>&nbsp;</p><p>Epcoritamab should be inspected visually for particulate matter and discolouration prior to administration. The solution for injection should be a colourless to slightly yellow solution. Do not use if the solution is discoloured, or cloudy, or if foreign particles are present.</p><p>&nbsp;</p><p><em>Preparation of epcoritamab</em></p><p>Epcoritamab has to be prepared using aseptic technique. Filtration of the diluted solution is not required.</p><p>&nbsp;</p><p><u>0.16&nbsp;mg priming dose preparation instructions &ndash; <strong>2 dilutions required</strong></u></p><p>Use an appropriately sized, syringe, vial, and needle for each transfer step.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p>1)&nbsp;&nbsp; Prepare epcoritamab vial</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retrieve one 4&nbsp;mg/0.8&nbsp;ml epcoritamab vial with the <strong>light blue</strong> cap from the refrigerator.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Allow the vial to come to room temperature for no more than 1&nbsp;hour.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the epcoritamab vial.</p><p><strong>DO NOT</strong> vortex or vigorously shake the vial.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2)&nbsp;&nbsp; Perform first dilution</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Label an appropriately sized empty vial as <strong>&ldquo;dilution A&rdquo;</strong>.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Transfer <strong>0.8</strong>&nbsp;<strong>ml of epcoritamab </strong>into the <strong>dilution A </strong>vial.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfer <strong>4.2</strong>&nbsp;<strong>ml of sodium chloride </strong><strong>9&nbsp;mg/ml (0.9%)</strong><strong> </strong><strong>sterile solution </strong>into the <strong>dilution A </strong>vial. The initial diluted solution contains 0.8&nbsp;mg/ml of epcoritamab.</p><p>d)&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the <strong>dilution A </strong>vial for 30 &ndash; 45&nbsp;seconds.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>3)&nbsp; Perform second dilution</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Label an appropriately sized empty vial as <strong>&ldquo;dilution B&rdquo;</strong>.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Transfer <strong>2</strong>&nbsp;<strong>ml of solution</strong> from the <strong>dilution A </strong>vial into the <strong>dilution B </strong>vial. The <strong>dilution A </strong>vial is no longer needed and should be discarded.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfer <strong>8</strong>&nbsp;<strong>ml of sodium chloride </strong><strong>9&nbsp;mg/ml (0.9%) </strong><strong>sterile solution</strong> into the <strong>dilution B </strong>vial to make a final concentration of 0.16&nbsp;mg/ml.</p><p>d)&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the <strong>dilution B </strong>vial for 30 &ndash; 45&nbsp;seconds.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4)&nbsp; Withdraw dose</p><p>Withdraw <strong>1</strong>&nbsp;<strong>ml of the diluted epcoritamab</strong> from the <strong>dilution B </strong>vial into a syringe. The <strong>dilution B</strong> vial is no longer needed and should be discarded.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5)&nbsp; Label syringe</p><p>Label the syringe with the product name, dose strength (0.16&nbsp;mg), date and the time of day. For storage of the diluted epcoritamab, see section 6.3.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6)&nbsp;&nbsp;&nbsp; Discard the vial and any unused portion of epcoritamab in accordance with local requirements.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>0.8&nbsp;mg intermediate dose preparation instructions &ndash; <strong>1 dilution required</strong></u></p><p>Use an appropriately sized syringe, vial and needle for each transfer step.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:684px"><tbody><tr><td style="vertical-align:top"><p>1)&nbsp;&nbsp; Prepare epcoritamab vial</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retrieve one 4&nbsp;mg/0.8&nbsp;ml epcoritamab vial with the <strong>light blue </strong>cap from the refrigerator.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Allow the vial to come to room temperature for no more than 1&nbsp;hour.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the epcoritamab vial.</p><p><strong>DO NOT</strong> vortex or vigorously shake the vial.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2)&nbsp;&nbsp; Perform dilution</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Label an appropriately sized empty vial as <strong>&ldquo;dilution A&rdquo;</strong>.</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Transfer <strong>0.8</strong>&nbsp;<strong>ml of epcoritamab</strong> into the <strong>dilution A</strong> vial.</p><p>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transfer <strong>4.2</strong>&nbsp;<strong>ml of sodium chloride </strong><strong>9&nbsp;mg/ml (0.9%) </strong><strong>sterile solution</strong> into the <strong>dilution A</strong> vial to make a final concentration of 0.8&nbsp;mg/ml.</p><p>d)&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl the <strong>dilution A </strong>vial for 30 &ndash; 45&nbsp;seconds.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>3)&nbsp;&nbsp; Withdraw dose</p><p>Withdraw <strong>1</strong>&nbsp;<strong>ml of the diluted epcoritamab</strong> from the <strong>dilution A </strong>vial into a syringe. The <strong>dilution A</strong> vial is no longer needed and should be discarded.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4)&nbsp;&nbsp; Label syringe</p><p>Label the syringe with the product name, dose strength (0.8&nbsp;mg), date and the time of day. For storage of the diluted epcoritamab, see section 6.3.<br />&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5)&nbsp;&nbsp;&nbsp; Discard the vial and any unused portion of epcoritamab in accordance with local requirements.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>3&nbsp;mg second intermediate dose preparation instructions- <strong>No dilution required</strong> </u></p><p>Epcoritamab 3&nbsp;mg dose is required for FL patients only (see<strong> </strong>Section 4.2).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>1) Prepare epcoritamab vial</p><p>a) Retrieve one 4&nbsp;mg/0.8&nbsp;ml epcoritamab vial with the <strong>light blue</strong> cap from the refrigerator.</p><p>b) Allow the vial to come to room temperature for no more than 1&nbsp;hour.</p><p>c) Gently swirl the epcoritamab vial.</p><p><strong>DO NOT</strong> vortex, or vigorously shake the vial.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2) Withdraw dose</p><p>Withdraw <strong>0.6&nbsp;ml of epcoritamab</strong> into a syringe.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>3) Label syringe</p><p>Label the syringe with the product name, dose strength (3&nbsp;mg), date and the time of day. For storage of the prepared epcoritamab, see section 6.3.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4) Discard the vial and any unused portion of epcoritamab in accordance with local requirements.</p></td></tr></tbody></table><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>